WO2008070447A2 - Anti-viral compounds - Google Patents

Anti-viral compounds Download PDF

Info

Publication number
WO2008070447A2
WO2008070447A2 PCT/US2007/085218 US2007085218W WO2008070447A2 WO 2008070447 A2 WO2008070447 A2 WO 2008070447A2 US 2007085218 W US2007085218 W US 2007085218W WO 2008070447 A2 WO2008070447 A2 WO 2008070447A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
heterocyclic
cycloalkyl
alkyl
aryl
Prior art date
Application number
PCT/US2007/085218
Other languages
French (fr)
Other versions
WO2008070447A3 (en
Inventor
Martin Robert Leivers
Franz Ulrich Schmitz
Christopher Don Roberts
Ali Dehghani Mohammad Abadi
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to EP07871535A priority Critical patent/EP2097405A2/en
Priority to US12/515,610 priority patent/US20100055071A1/en
Priority to JP2009537412A priority patent/JP2010510245A/en
Publication of WO2008070447A2 publication Critical patent/WO2008070447A2/en
Publication of WO2008070447A3 publication Critical patent/WO2008070447A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Disclosed are compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof of having Formula (I), their preparation, use, and compositions thereof for treating an infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, L1, V, W, T, Z, R, Y1, and p are as defined herein.

Description

ANTI-VIRAL COMPOUNDS
BACKGROUND OF THE INVENTION
Cross-Reference To Related Applications This application claims the benefit under 35 U. S. C. §119(e) to U.S. provisional applications serial No. 60/860,614 filed on November 21, 2006, which is incorporated herein by reference in its entirety.
Field of the Invention
The invention relates to the field of pharmaceutical chemistry, in particular to compounds, their preparation, compositions, and uses thereof for treating viral infections in patients mediated, at least in part, by a virus in the Flaviviridae family of viruses.
References
The following publications are cited in this application as superscript numbers:
1. Szabo, et al, Pathol. Oncol. Res. 2003, 9:215-221. 2. ϋoofnagle m, Hepatology 1997, 26:15S-20S.
3. Thomson BJ and Finch RG, Clin Microbial Infect. 2005, 11 :86-94.
4. Moriishi K and Matsuura Y, Antivir.Chem. Chemother. 2003, 14:285- 297.
5. Fried, et al. N. Engl. J Med 2002, 347:975-982. 6. Ni, Z. J. and Wagman, A. S. Curr. Opin. Drug Discov. Devel. 2004,
7, 446-459.
7. Beaulieu, P. L. and Tsantrizos, Y. S. Curr. Opin. Investig. Drugs 2004, 5, 838-850.
8. Griffith, et al. , Ann. Rep. Med. Chem 39, 223-237, 2004. 9. Watashi, et al, Molecular Cell, 19, 111-122, 2005
10. Horsmans, et al., Hepatology, 42, 724-731, 2005
All of the above publications are herein incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference in its entirety. State of the Art
Chronic infection with HCV is a major health problem associated with liver cirrhosis, hepatocellular carcinoma and liver failure. An estimated 170 million chronic carriers worldwide are at risk of developing liver disease.1'2 In the United States alone 2.7 million are chronically infected with HCV, and the number of HCV -related deaths in 2000 was estimated between 8,000 and 10,000, a number that is expected to increase significantly over the next years. Infection by HCV is insidious in a high proportion of chronically infected (and infectious) carriers who may not experience clinical symptoms for many years. Liver cirrhosis can ultimately lead to liver failure. Liver failure resulting from chronic HCV infection is now recognized as a leading cause of liver transplantation.
HCV is a member of the Flaviviridae family of RNA viruses that affect animals and humans. The genome is a single ~9.6-kilobase strand of RNA, and consists of one open reading frame that encodes for a polyprotein of -3000 amino acids flanked by untranslated regions at both 5' and 3' ends (5'- and 3'-UTR). The polyprotein serves as the precursor to at least 10 separate viral proteins critical for replication and assembly of progeny viral particles. The organization of structural and non-structural proteins in the HCV polyprotein is as follows: C-El-E2-p7-NS2-NS3-NS4a-NS4b-NS5a-NS5b. Because the replicative cycle of HCV does not involve any DNA intermediate and the virus is not integrated into the host genome, HCV infection can theoretically be cured. While the pathology of HCV infection affects mainly the liver, the virus is found in other cell types in the body including peripheral blood lymphocytes.3'4
At present, the standard treatment for chronic HCV is interferon alpha (IFN-alpha) in combination with ribavirin and this requires at least six (6) months of treatment. IFN- alpha belongs to a family of naturally occurring small proteins with characteristic biological effects such as antiviral, immunoregulatory and antitumoral activities that are produced and secreted by most animal nucleated cells in response to several diseases, in particular viral infections. IFN-alpha is an important regulator of growth and differentiation affecting cellular communication and immunological control. Treatment of HCV with interferon has frequently been associated with adverse side effects such as fatigue, fever, chills, headache, myalgias, arthralgias, mild alopecia, psychiatric effects and associated disorders, autoimmune phenomena and associated disorders and thyroid dysfunction. Ribavirin, an inhibitor of inosine 5 '-monophosphate dehydrogenase (IMPDH), enhances the efficacy of IFN-alpha in the treatment of HCV. Despite the introduction of ribavirin, more than 50% of the patients do not eliminate the virus with the current standard therapy of interferon-alpha (IFN) and ribavirin. By now, standard therapy of chronic hepatitis C has been changed to the combination of pegylated IFN-alpha plus ribavirin. However, a number of patients still have significant side effects, primarily related to ribavirin. Ribavirin causes significant hemolysis in 10-20% of patients treated at currently recommended doses, and the drug is both teratogenic and embryotoxic. Even with recent improvements, a substantial fraction of patients do not respond with a sustained reduction in viral load 5 and there is a clear need for more effective antiviral therapy of HCV infection. A number of approaches are being pursuit to combat the virus. They include, for example, application of antisense oligonucleotides or ribozymes for inhibiting HCV replication. Furthermore, low-molecular weight compounds that directly inhibit HCV proteins and interfere with viral replication are considered as attractive strategies to control HCV infection. Among the viral targets, the NS3/4A protease/helicase and the NS5b RNA- dependent RNA polymerase are considered the most promising viral targets for new drugs.6"
8
Besides targeting viral genes and their transcription and translation products, antiviral activity can also be achieved by targeting host cell proteins that are necessary for viral replication. For example, Watashi et al. 9 show how antiviral activity can be achieved by inhibiting host cell cyclophilins. Alternatively, a potent TLR7 agonist has been shown to reduce HCV plasma levels in humans. 10
However, none of the compounds described above have progressed beyond clinical trials. 6'8
Notwithstanding the above, the discovery of new compounds active against one or more members of the Flaviviridae family of viruses would be beneficial particularly in view of the difficulty currently faced in treating diseases mediated, at least in part, by one or more of such viruses.
SUMMARY OF THE INVENTION
This invention is directed to compounds, their preparation, compositions, prodrugs, and uses thereof for treating viral infections mediated, at least in part, by a virus in the Flaviviridae family of viruses. In one embodiment, provided is compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof, wherein:
Figure imgf000005_0001
A is a 3-13 membered ring optionally substituted with -(R )m wherein said ring is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl; each R2 is independently selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aryl, substituted aryl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, halo, hydroxy, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, nitro, thiol, alkylthio, and substituted alkylthio; m is 0, 1, 2, or 3;
L1 is a bond, C1-C3 alkylene, C1-C2 heteroalkylene, C2-C3 alkenylene, or C2-C3 alkynylene;
T is C2-C6 alkylene or C1-Cs heteroalkylene and forms a 4-8 membered ring with V and W;
V and W are both CH, or one of V or W is CH and the other of V or W is N; p is 0, 1 or 2; Y1 is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, halo, hydroxy, alkoxy, substituted alkoxy, =CH2, oxo, or two Y1 groups together with the atoms to which they are bound form a phenyl, 4-7 membered cycloalkyl, or 4-7 membered heterocyclic ring where the phenyl, cycloalkyl, or heterocyclic ring is itself optionally substituted with 1 to 2 Y2 groups;
Y2 is independently selected from the group consisting of alkyl, substituted alkyl, halo, oxo, hydroxy, carboxyl, carboxyl ester, cyano, and alkoxy with the proviso that Y is not oxo when the ring to which it is attached is phenyl; Z is selected from the group consisting of C(O), C(S), and -SO2-; R is selected from the group consisting of R1, OR1, OCH2R1, and NRlaR!; R1 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and Rla is selected from the group consisting of hydrogen, alkyl, and substituted alkyl.
In one embodiment provided is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound, stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof of Formula (I).
In one embodiment provided is a method for treating a viral infection in a patient mediated at least in part by a virus in the Flaviviridae family of viruses, comprising administering to said patient a composition of Formula (I). In some aspects, the viral infection is mediated by hepatitis C virus.
DETAILED DESCRIPTION Definitions As used herein, the following definitions shall apply unless otherwise indicated.
"Alkyl" refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH3-), ethyl (CHsCH2-), n-propyl (CH3CH2CH2-), isopropyl ((CHs)2CH-), n-butyl (CH3CH2CH2CH2-), isobutyl ((CHs)2CHCH2-), sec-butyl ((CH3)(CH3CH2)CH-), t-butyl ((CH3)3C-), n-pentyl (CH3CH2CH2CH2CH2-), and neopentyl ((CH3)3CCH2-).
"Alkenyl" refers to straight or branched hydrocarbyl groups having from 2 to 6 carbon atoms and preferably 2 to 4 carbon atoms and having at least 1 and preferably from 1 to 2 sites of vinyl (>C=C<) unsaturation. Such groups are exemplified, for example, by vinyl, allyl, and but-3-en-l-yl. Included within this term are the cis and trans isomers or mixtures of these isomers.
"Alkynyl" refers to straight or branched monovalent hydrocarbyl groups having from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms and having at least 1 and preferably from 1 to 2 sites of acetylenic (-C≡C-) unsaturation. Examples of such alkynyl groups include acetylenyl (-C≡CH), and propargyl (-CH2C≡CH). "Substituted alkyl" refers to an alkyl group having from 1 to 5, preferably 1 to 3, or more preferably 1 to 2 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl, substituted aryl, aryloxy, substituted aryloxy, arylthio, substituted arylthio, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkyloxy, substituted cycloalkyloxy, cycloalkylthio, substituted cycloalkylthio, cycloalkenyl, substituted cycloalkenyl, cycloalkenyloxy, substituted cycloalkenyloxy, cycloalkenylthio, substituted cycloalkenylthio, guanidino, substituted guanidino, halo, hydroxy, heteroaryl, substituted heteroaryl, hetero aryloxy, substituted heteroaryloxy, heteroarylthio, substituted heteroarylthio, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, heterocyclylthio, substituted heterocyclylthio, nitro, SO3H, substituted sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, and substituted alkylthio, wherein said substituents are as defined herein.
"Substituted alkenyl" refers to alkenyl groups having from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl, substituted aryl, aryloxy, substituted aryloxy, arylthio, substituted arylthio, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkyloxy, substituted cycloalkyloxy, cycloalkylthio, substituted cycloalkylthio, cycloalkenyl, substituted cycloalkenyl, cycloalkenyloxy, substituted cycloalkenyloxy, cycloalkenylthio, substituted cycloalkenylthio, guanidino, substituted guanidino, halo, hydroxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heteroarylthio, substituted heteroarylthio, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, heterocyclylthio, substituted heterocyclylthio, nitro, SO3H, substituted sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, and substituted alkylthio, wherein said substituents are as defined herein and with the proviso that any hydroxy substitution is not attached to a vinyl (unsaturated) carbon atom.
"Substituted alkynyl" refers to alkynyl groups having from 1 to 3 substituents, and preferably 1 to 2 substituents, selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl, substituted aryl, aryloxy, substituted aryloxy, arylthio, substituted arylthio, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkyloxy, substituted cycloalkyloxy, cycloalkylthio, substituted cycloalkylthio, cycloalkenyl, substituted cycloalkenyl, cycloalkenyloxy, substituted cycloalkenyloxy, cycloalkenylthio, substituted cycloalkenylthio, guanidino, substituted guanidino, halo, hydroxy, heteroaryl, substituted heteroaryl, hetero aryloxy, substituted heteroaryloxy, heteroarylthio, substituted heteroarylthio, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, heterocyclylthio, substituted heterocyclylthio, nitro, SO3H, substituted sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, and substituted alkylthio, wherein said substituents are as defined herein and with the proviso that any hydroxy substitution is not attached to an acetylenic carbon atom. "C2-C6 alkylene" refers to divalent straight chain alkyl groups having from 1 to 6 carbons.
"C1-Cs heteroalkylene" refers to alkylene groups where one or two -CH2- groups are replaced with -S-, or -O- to give a heteroalkylene having one to five carbons provided that the heteroalkylene does not contain an -O-O-, -S-O-, or -S-S- group. "Alkoxy" refers to the group -O-alkyl wherein alkyl is defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy.
"Substituted alkoxy" refers to the group -O-(substituted alkyl) wherein substituted alkyl is defined herein. "Acyl" refers to the groups H-C(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl-C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)-, cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, cycloalkenyl-C(O)-, substituted cycloalkenyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O)-, heterocyclic-C(O)-, and substituted heterocyclic-C(O)-, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein. Acyl includes the "acetyl" group CH3C(O)-.
"Acylamino" refers to the groups -NR47C(O)alkyl, -NR47C(O)substituted alkyl, -NR47C(O)cycloalkyl, -NR47C(O)substituted cycloalkyl, -NR47C(O)cycloalkenyl, -NR47C(O)substituted cycloalkenyl, -NR47C(O)alkenyl, -NR47C(O)substituted alkenyl, -NR47C(O)alkynyl, -NR47C(O)substituted alkynyl, -NR47C(O)aryl, -NR47C(O)substituted aryl, -NR47C(O)heteroaryl, -NR47C(O)substituted heteroaryl, -NR47C(O)heterocyclic, and -NR47C(O)substituted heterocyclic wherein R47 is hydrogen or alkyl and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Acyloxy" refers to the groups alkyl-C(O)O-, substituted alkyl-C(O)O-, alkenyl-C(O)O-, substituted alkenyl-C(O)O-, alkynyl-C(O)O-, substituted alkynyl-C(O)O-, aryl-C(O)O-, substituted aryl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, cycloalkenyl-C(O)O-, substituted cycloalkenyl-C(O)O-, heteroaryl-C(O)O-, substituted heteroaryl-C(O)O-, heterocyclic-C(O)O-, and substituted heterocyclic-C(O)O- wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Amino" refers to the group -NH2.
"Substituted amino" refers to the group -NR48R49 where R48 and R49 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, -SO2-alkyl, -SO2-substituted alkyl, -SO2-alkenyl, -SO2-substituted alkenyl, -SO2-cycloalkyl, -SO2-substituted cylcoalkyl, -SO2-cycloalkenyl, -SO2-substituted cylcoalkenyl,-SO2-aryl, -SO2-substituted aryl, -SO2-heteroaryl, -SO2-substituted heteroaryl, -SO2-heterocyclic, and -SO2-substituted heterocyclic and wherein R48 and R49 are optionally joined, together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, provided that R 48 and R49 are both not hydrogen, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein. When R is hydrogen and R49 is alkyl, the substituted amino group is sometimes referred to herein as alkylamino. When R48 and R49 are alkyl, the substituted amino group is sometimes referred to herein as dialkylamino. When referring to a monosubstituted amino, it is meant that either R48 or R49 is hydrogen but not both. When referring to a disubstituted amino, it is meant that neither R48 nor R49 are hydrogen. "Aminocarbonyl" refers to the group -C(O)NR50R51 where R50 and R51 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and where R50 and R51 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein. "Aminothiocarbonyl" refers to the group -C(S)NR50R51 where R50 and R51 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and where R50 and R51 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein. "Aminocarbonylamino" refers to the group -NR47C(O)NR50R51 where R47 is hydrogen or alkyl and R50 and R51 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic, and where R50 and R51 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Aminothiocarbonylamino" refers to the group -NR47C(S)NR50R51 where R is hydrogen or alkyl and R50 and R51 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and where R50 and R51 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Aminocarbonyloxy" refers to the group -0-C(O)NR50R51 where R50 and R51 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and where R50 and R51 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Aminosulfonyl" refers to the group -SO2NR50R51 where R50 and R51 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and where R50 and R51 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Aminosulfonyloxy" refers to the group -0-SO2NR50R51 where R50 and R51 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and where R50 and R51 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Aminosulfonylamino" refers to the group -NR47SO2NR50R51 where R47 is hydrogen or alkyl and R50 and R51 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and where R50 and R51 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Amidino" refers to the group -C(=NR52)NR50R51 where R50, R51, and R52 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic and where R50 and R51 are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Aryl" or "Ar" refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic provided that the point of attachment is at an aromatic carbon atom. Preferred aryl groups include phenyl and naphthyl.
"Substituted aryl" refers to aryl groups which are substituted with 1 to 5, preferably 1 to 3, or more preferably 1 to 2 substituents selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl, substituted aryl, aryloxy, substituted aryloxy, arylthio, substituted arylthio, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkyloxy, substituted cycloalkyloxy, cycloalkylthio, substituted cycloalkylthio, cycloalkenyl, substituted cycloalkenyl, cycloalkenyloxy, substituted cycloalkenyloxy, cycloalkenylthio, substituted cycloalkenylthio, guanidino, substituted guanidino, halo, hydroxy, heteroaryl, substituted heteroaryl, hetero aryloxy, substituted heteroaryloxy, heteroarylthio, substituted heteroarylthio, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, heterocyclylthio, substituted heterocyclylthio, nitro, SO3H, substituted sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, and substituted alkylthio, wherein said substituents are as defined herein. "Aryloxy" refers to the group -O-aryl, where aryl is as defined herein, that includes, by way of example, phenoxy and naphthoxy.
"Substituted aryloxy" refers to the group -O-(substituted aryl) where substituted aryl is as defined herein.
"Arylthio" refers to the group -S-aryl, where aryl is as defined herein. "Substituted arylthio" refers to the group -S-(substituted aryl), where substituted aryl is as defined herein. "Carbonyl" refers to the divalent group -C(O)- which is equivalent to -C(=O)-. "Carboxyl" or "carboxy" refers to -COOH or salts thereof.
"Carboxyl ester" or "carboxy ester" refers to the groups -C(O)O-alkyl, -C(O)O-substituted alkyl, -C(O)O-alkenyl, -C(O)O-substituted alkenyl, -C(O)O-alkynyl, -C(O)O-substituted alkynyl, -C(O)O-aryl, -C(O)O-substituted aryl, -C(O)O-cycloalkyl, -C(O)O-substituted cycloalkyl, -C(O)O-cycloalkenyl, -C(O)O-substituted cycloalkenyl, -C(O)O-heteroaryl, -C(O)O-substituted heteroaryl, -C(O)O-heterocyclic, and -C(O)O-substituted heterocyclic wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"(Carboxyl ester)amino" refers to the group -NR47C(O)O-alkyl,
-NR47C(O)O-substituted alkyl, -NR47C(O)O-alkenyl, -NR47C(O)O-substituted alkenyl, -NR47C(O)O-alkynyl, -NR47C(O)O-substituted alkynyl, -NR47C(O)O-aryl, -NR47C(O)O-substituted aryl, -NR47C(O)O-cycloalkyl, -NR47C(O)O-substituted cycloalkyl, -NR47C(O)O-cycloalkenyl, -NR47C(O)O-substituted cycloalkenyl, -NR47C(O)O-heteroaryl, -NR47C(O)O-substituted heteroaryl, -NR47C(O)O-heterocyclic, and -NR47C(O)O-substituted heterocyclic wherein R47 is alkyl or hydrogen, and wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"(Carboxyl ester)oxy" refers to the group -O-C(O)O-alkyl, -O-C(O)O-substituted alkyl, -O-C(O)O-alkenyl, -O-C(O)O-substituted alkenyl, -O-C(O)O-alkynyl, -O-C(O)O-substituted alkynyl, -O-C(O)O-aryl, -O-C(O)O-substituted aryl,
-O-C(O)O-cycloalkyl, -O-C(O)O-substituted cycloalkyl, -O-C(O)O-cycloalkenyl, -O-C(O)O-substituted cycloalkenyl, -O-C(O)O-heteroaryl, -O-C(O)O-substituted heteroaryl, -O-C(O)O-heterocyclic, and -O-C(O)O-substituted heterocyclic wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein. "Cyano" refers to the group -CN.
"Cycloalkyl" refers to cyclic alkyl groups of from 3 to 10 carbon atoms having single or multiple cyclic rings including fused, bridged, and spiro ring systems. One or more of the rings can be aryl, heteroaryl, or heterocyclic provided that the point of attachment is through the non-aromatic, non-heterocyclic ring carbocyclic ring (e.g. fluorenyl). Examples of suitable cycloalkyl groups include, for instance, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl.
"Cycloalkenyl" refers to non-aromatic cyclic alkyl groups of from 3 to 10 carbon atoms having single or multiple cyclic rings and having at least one >C=C< ring unsaturation and preferably from 1 to 2 sites of >C=C< ring unsaturation.
"Substituted cycloalkyl" and "substituted cycloalkenyl" refers to a cycloalkyl or cycloalkenyl group having from 1 to 5 or preferably 1 to 3 substituents selected from the group consisting of oxo, thioxo, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, aryl, substituted aryl, aryloxy, substituted aryloxy, arylthio, substituted arylthio, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkyloxy, substituted cycloalkyloxy, cycloalkylthio, substituted cycloalkylthio, cycloalkenyl, substituted cycloalkenyl, cycloalkenyloxy, substituted cycloalkenyloxy, cycloalkenylthio, substituted cycloalkenylthio, guanidino, substituted guanidino, halo, hydroxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heteroarylthio, substituted heteroarylthio, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, heterocyclylthio, substituted heterocyclylthio, nitro, SO3H, substituted sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, and substituted alkylthio, wherein said substituents are as defined herein.
"Cycloalkyloxy" refers to -O-cycloalkyl.
"Substituted cycloalkyloxy refers to -O-(substituted cycloalkyl). "Cycloalkylthio" refers to -S-cycloalkyl.
"Substituted cycloalkylthio" refers to -S-(substituted cycloalkyl). "Cycloalkenyloxy" refers to -O-cycloalkenyl.
"Substituted cycloalkenyloxy refers to -O-(substituted cycloalkenyl). "Cycloalkenylthio" refers to -S-cycloalkenyl.
"Substituted cycloalkenylthio" refers to -S-(substituted cycloalkenyl). "Guanidino" refers to the group -NHC(=NH)NH2.
"Substituted guanidino" refers to -NR53C(=NR53)N(R53)2 where each R53 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, and substituted heterocyclic and two R53 groups attached to a common guanidino nitrogen atom are optionally joined together with the nitrogen bound thereto to form a heterocyclic or substituted heterocyclic group, provided that at least one R53 is not hydrogen, and wherein said substituents are as defined herein.
"Halo" or "halogen" refers to fluoro, chloro, bromo and iodo and preferably is fluoro or chloro. "Haloalkyl" refers to alkyl groups substituted with 1 to 5, 1 to 3, or 1 to 2 halo groups, wherein alkyl and halo are as defined herein.
"Haloalkoxy" refers to alkoxy groups substituted with 1 to 5, 1 to 3, or 1 to 2 halo groups, wherein alkoxy and halo are as defined herein.
"Hydroxy" or "hydroxyl" refers to the group -OH. "Heteroaryl" refers to an aromatic group of from 1 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur within the ring. Such heteroaryl groups can have a single ring (e.g., pyridinyl or furyl) or multiple condensed rings (e.g. , indolizinyl or benzothienyl) wherein the condensed rings may or may not be aromatic and/or contain a heteroatom provided that the point of attachment is through an atom of the aromatic heteroaryl group. In one embodiment, the nitrogen and/or the sulfur ring atom(s) of the heteroaryl group are optionally oxidized to provide for the N-oxide (N→O), sulfmyl, or sulfonyl moieties. Preferred heteroaryls include pyridinyl, pyrrolyl, indolyl, thiophenyl, and furanyl. "Substituted heteroaryl" refers to heteroaryl groups that are substituted with from 1 to 5, preferably 1 to 3, or more preferably 1 to 2 substituents selected from the group consisting of the same group of substituents defined for substituted aryl.
"Heteroaryloxy" refers to -O-heteroaryl. "Substituted heteroaryloxy refers to the group -O-(substituted heteroaryl).
"Heteroarylthio" refers to the group -S-heteroaryl. "Substituted heteroarylthio" refers to the group -S -(substituted heteroaryl).
"Heterocycle" or "heterocyclic" or "heterocycloalkyl" or "heterocyclyl" refers to a saturated or partially saturated, but not aromatic, group having from 1 to 10 ring carbon atoms and from 1 to 4 ring heteroatoms selected from the group consisting of nitrogen, sulfur, or oxygen. Heterocycle encompasses single ring or multiple condensed rings, including fused, bridged, and spiro ring systems. In fused ring systems, one or more the rings can be cycloalkyl, aryl, or heteroaryl provided that the point of attachment is through the non-aromatic ring. In one embodiment, the nitrogen and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, sulfmyl, or sulfonyl moieties.
"Substituted heterocyclic" or "substituted heterocycloalkyl" or "substituted heterocyclyl" refers to heterocyclyl groups that are substituted with from 1 to 5 or preferably 1 to 3 of the same substituents as defined for substituted cycloalkyl. "Heterocyclyloxy" refers to the group -O-heterocycyl.
"Substituted heterocyclyloxy refers to the group -O-(substituted heterocycyl).
"Heterocyclylthio" refers to the group -S-heterocycyl.
"Substituted heterocyclylthio" refers to the group -S-(substituted heterocycyl).
Examples of heterocycle and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophene, morpholinyl, thiomorpholinyl (also referred to as thiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidine, and tetrahydrofuranyl.
"Nitro" refers to the group -NO2. "Oxo" refers to the atom (=0) or (-0 ).
"Spiro ring systems" refers to bicyclic ring systems that have only a single ring atom common to both rings.
"Sulfonyl" refers to the divalent group -S(O)2-.
"Substituted sulfonyl" refers to the group -SO2-alkyl, -SO2-substituted alkyl, -SO2-alkenyl, -SO2-substituted alkenyl, -SO2-cycloalkyl, -SO2-substituted cylcoalkyl, -SO2-cycloalkenyl, -SO2-substituted cylcoalkenyl, -SO2-aryl, -SO2-substituted aryl, -SO2-heteroaryl, -SO2-substituted heteroaryl, -SO2-heterocyclic, -SO2-substituted heterocyclic, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein. Substituted sulfonyl includes groups such as methyl-SO2-, phenyl-SO2-, and 4-methylphenyl-SO2-.
"Sulfonyloxy" refers to the group -OSO2-alkyl, -OSO2-substituted alkyl, -OSO2-alkenyl, -OSO2-substituted alkenyl, -OSO2-cycloalkyl, -OSO2-substituted cylcoalkyl, -OSO2-cycloalkenyl, -OSO2-substituted cylcoalkenyl,-OSO2-aryl, -OSO2-substituted aryl, -OSO2-heteroaryl, -OSO2-substituted heteroaryl, -OSO2-heterocyclic, -OSO2-substituted heterocyclic, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Thioacyl" refers to the groups H-C(S)-, alkyl-C(S)-, substituted alkyl-C(S)-, alkenyl-C(S)-, substituted alkenyl-C(S)-, alkynyl-C(S)-, substituted alkynyl-C(S)-, cycloalkyl-C(S)-, substituted cycloalkyl-C(S)-, cycloalkenyl-C(S)-, substituted cycloalkenyl-C(S)-, aryl-C(S)-, substituted aryl-C(S)-, heteroaryl-C(S)-, substituted heteroaryl-C(S)-, heterocyclic-C(S)-, and substituted heterocyclic-C(S)-, wherein alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein.
"Thiol" refers to the group -SH. "Thiocarbonyl" refers to the divalent group -C(S)- which is equivalent to -C(=S)-.
"Thioxo" refers to the atom (=S). "Alkylthio" refers to the group -S-alkyl wherein alkyl is as defined herein.
"Substituted alkylthio" refers to the group -S-(substituted alkyl) wherein substituted alkyl is as defined herein. "Stereoisomer" or "stereoisomers" refer to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers.
"Tautomer" refer to alternate forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring -NH- moiety and a ring =N- moiety such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.
"Metabolite" refers to any derivative produced in a subject after administration of a parent compound. The metabolite may be produced from the parent compound by various biochemical transformations in the subject such as, for example, oxidation, reduction, hydrolysis, or conjugation. Metabolites include, for example, oxides and demethylated derivatives.
"Prodrug" refers to art recognized modifications to one or more functional groups which functional groups are metabolized in vivo to provide a compound of this invention or an active metabolite thereof. Such functional groups are well known in the art including acyl groups for hydroxyl and/or amino substitution, esters of mono-, di- and tri-phosphates wherein one or more of the pendent hydroxyl groups have been converted to an alkoxy, a substituted alkoxy, an aryloxy or a substituted aryloxy group, and the like.
"Patient" refers to mammals and includes humans and non-human mammals.
"Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, and oxalate [see Stahl and Wermuth, eds., "Handbook of Pharmaceutically Acceptable Salts", (2002), Verlag Helvetica Chimica Acta, Zurich, Switzerland, for an extensive discussion of pharmaceutical salts, their selection, preparation, and use].
"Therapeutically effective amount" is an amount sufficient to treat a specified disorder or disease.
"Treating" or "treatment" of a disease in a patient refers to 1) preventing the disease from occurring in a patient that is predisposed or does not yet display symptoms of the disease; 2) inhibiting the disease or arresting its development; or 3) ameliorating or causing regression of the disease.
Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent "arylalkyloxycarbonyl" refers to the group (aryl)-(alkyl)-O-C(O)-.
It is understood that in all substituted groups defined above, polymers arrived at by defining substituents with further substituents to themselves are not intended for inclusion herein. In such cases, the maximum number of such substitutions is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to -substituted aryl-(substituted aryl)-substituted aryl.
Similarly, it is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups). Such impermissible substitution patterns are well known to the skilled artisan. Accordingly, the present invention provides a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof, wherein:
Figure imgf000020_0001
A is a 3-13 membered ring optionally substituted with -(R )m wherein said ring is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl; each R is independently selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aryl, substituted aryl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, halo, hydroxy, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, nitro, thiol, alkylthio, and substituted alkylthio; m is O, 1, 2, or 3;
L1 is a bond, C1-C3 alkylene, C1-C2 heteroalkylene, C2-C3 alkenylene, or C2-C3 alkynylene;
T is C2-C6 alkylene or C1-Cs heteroalkylene and forms a 4-8 membered ring with V and W; V and W are both CH, or one of V or W is CH and the other of V or W is N; p is 0, 1 or 2;
Y1 is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, halo, hydroxy, alkoxy, substituted alkoxy, =CH2, oxo, or two Y1 groups together with the atoms to which they are bound form a phenyl, 4-7 membered cycloalkyl, or 4-7 membered heterocyclic ring where the phenyl, cycloalkyl, or heterocyclic ring is itself optionally substituted with 1 to 2 Y2 groups;
Y2 is independently selected from the group consisting of alkyl, substituted alkyl, halo, oxo, hydroxy, carboxyl, carboxyl ester, cyano, and alkoxy with the proviso that Y is not oxo when the ring to which it is attached is phenyl; Z is selected from the group consisting of C(O), C(S), and -SO2-; R is selected from the group consisting of R1, OR1, OCH2R1, and NRlaR!; R1 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and Rla is selected from the group consisting of hydrogen, alkyl, and substituted alkyl.
In one aspect, A is selected from the group consisting of
Figure imgf000022_0001
In one embodiment, provided is a compound of Formula (II) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof, wherein:
Figure imgf000022_0002
one of E or F is -N= and the other of E or F is -S-, -O- or -NH-; each R2 is independently selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aryl, substituted aryl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, halo, hydroxy, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, nitro, thiol, alkylthio, and substituted alkylthio; m is 1 or 2;
L1 is a bond, C1-C3 alkylene, C1-C2 heteroalkylene, C2-C3 alkenylene, or C2-C3 alkynylene;
T is C2-C6 alkylene or C1-Cs heteroalkylene and forms a 4-8 membered ring with V and W; V and W are both CH, or one of V or W is CH and the other of V or W is N; p is 0, 1 or 2;
Y1 is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, halo, hydroxy, alkoxy, substituted alkoxy, =CH2, oxo, or two Y1 groups together with the atoms to which they are bound form a phenyl, 4-7 membered cycloalkyl, or 4-7 membered heterocyclic ring where the phenyl, cycloalkyl, or heterocyclic ring is itself optionally substituted with 1 to 2 Y2 groups;
Y2 is independently selected from the group consisting of alkyl, substituted alkyl, halo, oxo, hydroxy, carboxyl, carboxyl ester, cyano, and alkoxy with the proviso that Y is not oxo when the ring to which it is attached is phenyl; Z is selected from the group consisting of C(O), C(S), and -SO2-; R is selected from the group consisting of R1, OR1, OCH2R1, and NRlaR!; R1 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and Rla is selected from the group consisting of hydrogen, alkyl, and substituted alkyl.
In some aspects of the compound, stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof of Formula (I) and (II), V is C and W is N. In other aspects, T is -CH2CH2CH2-.
In one embodiment, provided is a compound of Formula (III) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof, wherein:
Figure imgf000024_0001
one of E or F is -N= and the other of E or F is -S-, -O- or -NH-; each R2 is independently selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aryl, substituted aryl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, halo, hydroxy, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, nitro, thiol, alkylthio, and substituted alkylthio; m is 1 or 2; L1 is a bond, C1-C3 alkylene, C1-C2 heteroalkylene, C2-C3 alkenylene, or C2-C3 alkynylene;
Q is selected from the group consisting of CH2, CH(Y1), C(Y1XY1), S, and O; p is 0, 1 or 2;
Y1 is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, halo, hydroxy, alkoxy, substituted alkoxy, =CH2, oxo, or two Y1 groups together with the atoms to which they are bound form a phenyl, 4-7 membered cycloalkyl, or 4-7 membered heterocyclic ring where the phenyl, cycloalkyl, or heterocyclic ring is itself optionally substituted with 1 to 2 Y2 groups;
Y2 is independently selected from the group consisting of alkyl, substituted alkyl, halo, oxo, hydroxy, carboxyl, carboxyl ester, cyano, and alkoxy with the proviso that Y is not oxo when the ring to which it is attached is phenyl;
Z is selected from the group consisting of C(O), C(S), and -SO2-; R is selected from the group consisting of R1 , OR1 , OCH2R1 , and NRlaR! ;
R1 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and
Rla is selected from the group consisting of hydrogen, alkyl, and substituted alkyl. In some aspects of the compounds, stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof of Formula (III), Q is S, CH2, or O.
In some aspects of the compound, stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof of Formula (I), (II), or (III), L1 is a bond. In other aspects, L1 is C2 alkynylene.
In some aspects at least one of R2 is R3-L- wherein R3 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; and L, defined in the R3-L- orientation, is selected from the group consisting of a bond, -O-, -S-, -CH2-, -CH2CH2-, -SCH2-, -C(O)-, -C(S)-, -NHC(O)-, -C(O)NH-, -SO2-, -SO2NH-, -SO2CH2-, -OCH2-, -CH2CH2NHC(O)-,
-CH2CH2NHC(O)CH2-, -NHN=C(CH3CH2OCO)-, -NHSO2-, =CH-, -NHC(O)CH2S-, -NHC(O)CH2C(O)-, spirocycloalkyl, -C(O)CH2S-, and -C(O)CH2O- provided that when L is =CH-, R3 is heterocyclic or substituted heterocyclic. In some aspects, L is a bond.
In some aspects, R3 is substituted phenyl. In some such aspects, said phenyl is substituted with one to three groups independently selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, aryloxy, substituted aryloxy, alkylthio, substituted alkyl thio, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, substituted aryl, carboxyl, carboxyl ester, cyano cycloalkyl, substituted cycloalkyl, halo, hydroxy, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, nitro, thiol, alkylthio, and substituted alkylthio. In some aspects, at least one substitutent is cycloalkyl-C(O)NH-.
In some aspects, R3 is phenyl substituted with at least one group substituent selected from cyclopropyl-C(O)NH-, phenyl-C(O)NH-, cyclopentyl-C(O)NH-, 4-chlorophenyl- C(O)NH-, 4-chlorophenyl-C(O)NH-, methyl-C(O)NH-, methylamino, 4-methylphenyl- SO2NH-, amino, ethyl-C(O)NH-, bromo, methoxy, methyl-SO2NH-, chloro, phenyl-
SO2NH-, methyl-C(O)NH-, methyl-C(O)-, fluoro, methyl, ethyl, propyl, 4-fluorophenyl, nitro, phenyl, 4-bromobenzyloxy, cyclohexyl, isopropyl, tert-butyl, 4-methylpentyloxymethyl, NH2C(O)-, hydroxy, cyclohexyl-NHC(O)CH2S-, allyl, ethoxycarbonylmethylthio, dimethylamino, 3-nitro-phenyl, isobutyl, propoxy, butoxymethyl, butyl-C(O)NH-, methyl-NHC(O)-, ethyl-NHC(O)-, (2-oxo-hexahydro- thieno[3,4-d]imidazol-4-yl)-butyl-C(O)NH-, cyclopropyl-NHC(O)-, cyclohexyl-NHC(O)-, cyclopentyl-NHC(O)-, propyl, isobutyl, carboxy, pentyl-C(O)NH-, phenylamino-C(O)-, cylopropylamino-C(O)-, isopropylamino-C(O)-, and ethylamino-C(O)-.
In some aspects, Z is C(O).
In other aspects, R is OCH2R1 and R1 is phenyl or substituted phenyl.
In other aspects, p is 1 and Y1 is selected from the group consisting of substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, and substituted heterocyclic.
In other aspects Y1 is phenyl, pyridyl, substituted phenyl, or substituted pyridyl.
In other aspects Y1 is pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 3-fluoro-pyridin-4-yl-, 2-hydroxy-pyridin-4-yl, tetrahydro-pyran-4-ylmethyl, phenyl, 2-fluoro-phenyl, 3-fluoro- phenyl, 4 -fluorophenyl, 3-carboxy-phenyl, 4-carboxy-phenyl, 3-methoxycarbonyl-phenyl, 4-methoxycarbonyl-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, phenylmethyl, quinolin-4-yl, thiazol-2-yl, 3-cyano-phenyl, 4-cyano-phenyl, piperidin-3-yl-, piperidin-4-yl, pyrimidin-5-yl-, tetrahydro-pyran-4-yl, 2-chloro-pyridin-4-yl, cyclohexyl, oxazol-5-yl, 4-morpholin-4-ylmethyl-phenyl, 1 -methyl- lH-imidazol-2-yl, or oxazol-2-yl.
In yet other embodiments, the present invention provides a compound, stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof selected from Table 1.
Table 1
Figure imgf000026_0001
-
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
-
-
Figure imgf000032_0001
Figure imgf000033_0001
-
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
-
Figure imgf000037_0001
In one embodiment provided is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound, stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof of any one of Formula (I)-(III) or of the compounds in Table 1. In another embodiment provided is a method for treating a viral infection in a patient mediated at least in part by a virus in the Flaviviridae family of viruses, comprising administering to said patient such compositions. In some aspects, the viral infection is mediated by hepatitis C virus.
In other aspects, the administration of a therapeutically effective amount of the compounds and/or compositions of the invention are used in combination with one or more agents active against hepatitis C virus. These agent include an inhibitor of HCV proteases, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, or inosine 5 '-monophosphate dehydrogenase. In other embodiments, the agent is interferon.
Administration and Pharmaceutical Composition
In general, the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The actual amount of the compound of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, and other factors. The drug can be administered more than once a day, preferably once or twice a day. All of these factors are within the skill of the attending clinician.
Therapeutically effective amounts of compounds of Formula (I)-(III) may range from approximately 0.05 to 50 mg per kilogram body weight of the recipient per day; preferably about 0.1-25 mg/kg/day, more preferably from about 0.5 to 10 mg/kg/day. Thus, for administration to a 70 kg person, the dosage range would most preferably be about 35- 70 mg per day.
In general, compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen that can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions. Another preferred manner for administering compounds of this invention is inhalation. This is an effective method for delivering a therapeutic agent directly to the respiratory tract (see U. S. Patent 5,607,915).
The choice of formulation depends on various factors such as the mode of drug administration and bioavailability of the drug substance. For delivery via inhalation the compound can be formulated as liquid solution, suspensions, aerosol propellants or dry powder and loaded into a suitable dispenser for administration. There are several types of pharmaceutical inhalation devices-nebulizer inhalers, metered dose inhalers (MDI) and dry powder inhalers (DPI). Nebulizer devices produce a stream of high velocity air that causes the therapeutic agents (which are formulated in a liquid form) to spray as a mist that is carried into the patient's respiratory tract. MDFs typically are formulation packaged with a compressed gas. Upon actuation, the device discharges a measured amount of therapeutic agent by compressed gas, thus affording a reliable method of administering a set amount of agent. DPI dispenses therapeutic agents in the form of a free flowing powder that can be dispersed in the patient's inspiratory air-stream during breathing by the device. In order to achieve a free flowing powder, the therapeutic agent is formulated with an excipient such as lactose. A measured amount of the therapeutic agent is stored in a capsule form and is dispensed with each actuation.
Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No. 4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 nm in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Patent No. 5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
The compositions are comprised of in general, a compound of Formula (I)-(III) in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of Formula (I)-(III). Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols. Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990). The amount of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt%) basis, from about 0.01-99.99 wt% of a compound of Formula (I)-(III) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt%. Representative pharmaceutical formulations containing a compound of Formula (I)-(III) are described below.
Additionally, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of another active agent against RNA- dependent RNA virus and, in particular, against HCV.
References herein to agents active against HCV include, but are not limited to, ribavirin, levovirin, viramidine, thymosin alpha- 1, an inhibitor of HCV NS3 serine protease, interferon-α, pegylated interferon-α (peginterferon-α), a combination of interferon-α and ribavirin, a combination of peginterferon-α and ribavirin, a combination of interferon-α and levovirin, and a combination of peginterferon-α and levovirin. Interferon-α includes, but is not limited to, recombinant interferon-α2a (such as Roferon interferon available from
Hoffman-LaRoche, Nutley, NJ), interferon-α2b (such as Intron-A interferon available from Schering Corp., Kenilworth, New Jersey, USA), a consensus interferon, and a purified interferon-α product. For a discussion of ribavirin and its activity against HCV, see J. O. Saunders and S. A. Raybuck, "Inosine Monophosphate Dehydrogenase: Consideration of Structure, Kinetics and Therapeutic Potential," Ann. Rep. Med. Chem., 35:201-210 (2000). The agents active against hepatitis C virus also include agents that inhibit HCV proteases, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and inosine 5 '-monophosphate dehydrogenase. Other agents include nucleoside analogs for the treatment of an HCV infection. Still other compounds include those disclosed in WO 2004/014313 and WO 2004/014852 and in the references cited therein. The patent applications WO 2004/014313 and WO 2004/014852 are hereby incorporated by references in their entirety.
Specific antiviral agents include Omega IFN (BioMedicines Inc.), BILN-2061 (Boehringer Ingelheim), Summetrel (Endo Pharmaceuticals Holdings Inc.), Roferon A (F. Hoffman-La Roche), Pegasys (F. Hoffman-La Roche), Pegasys/Ribaravin (F. Hoffman-La Roche), CellCept (F. Hoffman-La Roche), Wellferon (GlaxoSmithKline), Albuferon-α (Human Genome Sciences Inc.), Levovirin (ICN Pharmaceuticals), IDN-6556 (Idun Pharmaceuticals), IP-501 (Indevus Pharmaceuticals), Actimmune (InterMune Inc.), Infergen A (InterMune Inc.), ISIS 14803 (ISIS Pharamceuticals Inc.), JTK-003 (Japan Tobacco Inc.), Pegasys/Ceplene (Maxim Pharmaceuticals), Ceplene (Maxim Pharmaceuticals), Civacir (Nabi Biopharmaceuticals Inc.), Intron A/Zadaxin (RegeneRx), Levovirin (Ribapharm Inc.), Viramidine(Ribapharm Inc.), Heptazyme (Ribozyme Pharmaceuticals), Intron A (Schering-Plough), PEG-Intron (Schering-Plough), Rebetron (Schering-Plough), Ribavirin (Schering-Plough), PEG-Intron/Ribavirin (Schering-Plough), Zadazim (SciClone), Rebif (Serono), IFN-β/EMZ701 (Transition Therapeutics), T67 (Tularik Inc.), VX-497 (Vertex Pharmaceuticals Inc.), VX-950/LY-570310 (Vertex Pharmaceuticals Inc.), Omniferon (Viragen Inc.), XTL-002 (XTL Biopharmaceuticals), SCH 503034 (Schering-Plough), isatoribine and its prodrugs ANA971 and ANA975 (Anadys), Rl 479 (Roche Biosciences), Valopicitabine (Idenix), NIM811 (Novartis), and Actilon (Coley Pharmaceuticals).
In some embodiments, the compositions and methods of the present invention contain a compound of Formula (I)-(III) and interferon. In some aspects, the interferon is selected from the group consisting of interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau. In other embodiments the compositions and methods of the present invention contain a compound of Formula (I)-(III) and a compound having anti-HC V activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
General Synthetic Methods
The compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein.
Furthermore, the compounds of this invention contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this invention, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well- known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents and the like. The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Emka-Chemce or Sigma (St. Louis, Missouri, USA). Others may be prepared by procedures, or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplemental (Elsevier Science
Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
The various starting materials, intermediates, and compounds of the invention may be isolated and purified where appropriate using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Characterization of these compounds may be performed using conventional methods such as by melting point, mass spectrum, nuclear magnetic resonance, and various other spectroscopic analyses. The preparation of various intermediates of the invention may involved one or more amide bond forming reactions. A variety of amide coupling reagents may be used to from the amide bond, including the use of carbodiimides such as N-N'-dicyclohexylcarbodiimide (DCC), N-N'-diisopropylcarbodiimide (DIPCDI), and l-ethyl-3-(3'- dimethylaminopropyl)carbodiimide (EDCI). The carbodiimides may be used in conjunction with additives such as benzotriazoles 7-aza-l-hydroxybenzotriazole (HOAt), 1- hydroxybenzotriazole (HOBt), and 6-chloro-l-hydroxybenzotriazole (Cl-HOBt).
Amide coupling reagents also include amininum and phosphonium based reagents. Aminium salts include N-[(dimethylamino)-lH-l,2,3-triazolo[4,5-b]pyridine-l- ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU), N- [(I H- benzotriazol- 1 -yl)(dimethylamino)methylene] -N-methylmethanaminium hexafluorophosphate N-oxide (HBTU), N-[(lH-6-chlorobenzotriazol-l- yl)(dimethylamino)methylene] -N-methylmethanaminium hexafluorophosphate N-oxide (HCTU), N- [( 1 H-benzotriazol- 1 -yl)(dimethylamino)methylene] -N-methylmethanaminium tetrafluoroborate N-oxide (TBTU), and N-[(lH-6-chlorobenzotriazol-l- yl)(dimethylamino)methylene]-N-methylmethanaminium tetrafluoroborate N-oxide (TCTU). Phosphonium salts include 7-azabenzotriazol-l-yl-N-oxy- tris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP) and benzotriazol-1-yl-N-oxy- tris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP).
The amide formation step may be conducted in a polar solvent such as dimethylformamide (DMF) and may also include an organic base such as diisopropylethylamine (DIPEA).
Scheme 1
Figure imgf000044_0001
Scheme 1 shows a general synthesis of compounds of the invention where, for illustrative purposes ring A is a substituted phenyl ring, p is 0, and Z-R together form a benzyloxycarbonyl group. Reaction of halide 1.1 with an azide such as sodium azide gives
1.2 that is then treated with a reducing agent such as PI13P to form imine 1.3. Exposure of
1.3 to a reducing agent such as sodium borohydride gives amine 1.4 that is then functionalized such as by reacting carbonylbenzyloxy chloride to give carbamate 1.5. Reaction of intermediate 1.5 with an aryl boronic acid or a suitable coupling partner in a transition metal catalyzed cross-coupling reaction gives compound 1.6. Suitable transition metal catalysts include Pd based catalysts (e.g. Pd(PPh3 )2C12, Pd[P(Ph3)]4, etc.) such as those used in a Suzuki coupling. Intermediate 1.5 can also be further modified to yield the compounds of the invention using methods that will be apparent to one of skill in the art. Scheme 2
Figure imgf000045_0001
Scheme 2 shows the general synthesis of compounds where, for illustrative purposes, L1 is C2 alkynylene, ring A is a substituted phenyl ring, p is 0, and Z-R together form a benzyloxycarbonyl group. Prolinol 2.1 is exposed to oxidizing conditions such as a Swern oxidation to form aldehyde 2.2. Reaction of the aldehyde with Bestmann-Ohira reagent 2.3 in the presence of a base such as an alkoxide gives alkyne 2.4. Reaction of 2.4 with iodide 2.5 under Sonogashira coupling conditions (Cu(I), Et3N, Pd(O)) gives boronic acid 2.4 that can then be coupled with Ar-X where X is a halide under Suzuki coupling conditions to give compound 2.7.
Figure imgf000045_0002
Scheme 3 shows the general synthesis of compounds where, for illustrative purposes, ring A is a substituted benzimidazole-2-yl, benzoxazole-2-yl, or benzthiazole-2- yl, p is 0, and Z-R together form a benzyloxycarbonyl group. Acid 3.1 is coupled with amine 3.2 in the presence of a coupling reagent such as HATU to give 3.2. Treatment of 3.3 with an acid such as acetic acid gives the cyclized halide 3.4 that can then be coupled with Ar-X where X is a halide under Suzuki coupling conditions to give compound 3.5.
The foregoing and other aspects of the present invention may be better understood in connection with the following representative examples.
EXAMPLES
The examples below as well as throughout the application, the following abbreviations have the following meanings. If not defined, the terms have their generally accepted meanings. atm = atmospheres cm = centimeter
DMF = dimethylformamide
DIPEA = diisopropylethylamine
DMSO = dimethylsulfoxide eq. = Equivalents
F.W. = Formula weight g = gram
HATU = N- [(dimethylamino)- 1 H- 1 ,2,3 - triazolo [4,5 -b]pyridine- 1 - ylmethylene] -N- methylmethanaminium hexafluorophosphate N-oxide
HPLC = high pressure liquid chromatography
KOAc = potassium acetate
L = liter
MeCN = acetonitrile mg = milligram mL = milliliter mmol = millimole
MS = mass spectrum
TEA = triethylamine
TFA = trifluoro acetic acid
THF = tetrahydrofuran
TLC = thin layer chromatography v/v = volume/volume μL = microliter
General Procedure A
A solution of 2-[6-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- benzoimidazol-2-yl] -pyrrolidine- 1-carboxylic acid benzyl ester (lOOmg, 0.220 mmol), aryl boronic acid (1 eq), Pd[P(Ph)3]4 (5 mol %, 13 mg), in methanol (2 mL), NaHCO3 (sat. aq., 300 μL) and DMF (400 μL) was degassed and heated to 70 0C overnight in a sealed vial. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the products.
General Procedure B A solution of 2-(6-bromo- 1 H-benzoimidazol-2-yl)-pyrrolidine- 1 -carboxylic acid benzyl ester (lOOmg, 0.25 mmol), aryl boronic acid (1 eq), Pd[P(Ph)3J4 (5 mol %, 14 mg), in methanol (2 mL), NaHCO3 (sat. aq., 300 μL) and DMF (400 μL) was degassed and heated to 70 0C overnight in a sealed vial. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the products.
General Procedure C
(S)-2-(5-Bromo-2-hydroxy-phenylcarbamoyl)-pyrrolidine-l-carboxylic acid benzyl ester.
Z-protected (S)-proline (664 mg) was dissolved in DMF (15 mL) and treated with HATU (1.1 eq. 1000 mg) and DIPEA (2.1 eq, 1 mL) and stirred for 15 minutes. Then 2- amino-4-bromo-phenol (1 eq, 500 mg) was added and the mixture stirred at ambient temperature overnight. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. MS: 419.5 (M+H+) (S)-2-(5-Bromo-benzooxazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester.
2-(5-Bromo-2-hydroxy-phenylcarbamoyl)-pyrrolidine-l -carboxylic acid benzyl ester (from above) was dissolved in HOAc (50 mL) and heated to 110 0C for 12 hours. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. MS : 401.5 (M+H+).
(S)-2-(6-aryl-benzooxazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester.
A solution of (S)-2-(5-Bromo-benzooxazol-2-yl)-pyrrolidine-l -carboxylic acid benzyl ester (80mg, 0.2 mmol), aryl boronic acid (1 eq), Pd[P(Ph)3J4 (5 mol %, 11 mg), in methanol (2 mL), NaHCO3 (sat. aq., 300 μL) and DMF (400 μL) was degassed and heated to 70 0C overnight in a sealed vial. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the products.
General Procedure D
2-Amino-5-bromo-benzenethiol. 6-Bromo-benzothiazol-2-ylamine (Ig) was dissolved in ethylene glycol (4 mL) treated with KOH aq. (4 mL, 10M) and heated to 125 deg. C for 12 hours. The reaction was cooled, filtered, neutralized with HOAc and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. MS: 204.5 (M+H+). (S)-2-(2-Amino-5-bromo-phenylsulfanylcarbonyl)-pyrrolidine-l-carboxylic acid benzyl ester.
Z-protected (S)-proline (1.35 g) was dissolved in DMF (5 mL) and treated with HBTU (1.1 eq. 2.3 g) and DIPEA (2.1 eq, 2.5 mL) and stirred for 15 minutes. Then 2- Amino-5-bromo-benzenethiol (1 eq, 1.1 g) was added and the mixture stirred at ambient temperature overnight. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. MS: 435.5 (M+H+)
(S)-2-(6-Bromo-benzothiazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester.
2-(2-Amino-5-bromo-phenylsulfanylcarbonyl)-pyrrolidine- 1 -carboxylic acid benzyl ester (from above) cyclized spontaneously in the refrigerator over one week. Used directly for the following reactions. MS: 417.5 (M+H+).
(S)-2-(6-aryl-benzothiazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester.
A solution of (S)-2-(6-Bromo-benzothiazol-2-yl)-pyrrolidine-l -carboxylic acid benzyl ester (83mg, 0.2 mmol), aryl boronic acid (1 eq), Pd[P(Ph)3J4 (5 mol %, 11 mg), in methanol (2 mL), NaHCO3 (sat. aq., 300 μL) and DMF (400 μL) was degassed and heated to 70 0C overnight in a sealed vial. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the products. Example 1
(S)-2-[6-(3-Cyclopropylcarbamoyl-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l- carboxylic acid benzyl ester (Compound 4001)
3-Bromo-N-cyclopropyl-benzamide 3-Bromo-benzoic acid (2.5518 g, 12.7 mmol) and HATU (5.2230 g, 13.7 mmol) were dissolved in DMF (40 rnL). DIPEA (4.644 rnL, 26.7 mmol) was added, and the mixture was allowed to stir at room temperature for 15 minutes. Then cyclopropylamine (0.88 mL, 12.7 mmol) was added, and the reaction was stirred at ambient temperature overnight. The solvent was removed, and the crude was purified via silica gel chromatography to yield the desired product.
(S)-2-[5-(4,4,5,5-Tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-benzoimidazol-2-yl]- pyrrolidine-1-carboxylic acid benzyl ester.
To a solution of (S)-2-(5-Bromo-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (3.5g, 8.75 mmol) in DMSO (20 mL) was added KOAc (2.5g), 4,4,5,5,4>,4>,5>,5>-Octamethyl-[2,2']bi[[l,3,2]dioxaborolanyl] (5.8g), NaHCO3 (900 mg), PdP(Ph)2Cl2 (600 mg) and heated to 80 C overnight. The mixture was precipitated by pouring into 20 mL of water, filtered, loaded onto a silica column and the product eluted at 20% EtOAc in hexanes. MS: 448 (M+H+).
(S)-2-[5-(3-Cyclopropylcarbamoyl-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l- carboxylic acid benzyl ester (Compound 4001)
A solution of (S)-2-[5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- benzoimidazol-2-yl]-pyrrolidine-l -carboxylic acid benzyl ester (90 mg, 0.20 mmol), 3- bromo-N-cyclopropyl-benzamide (48.6 mg, 0.20 mmol), and Pd[P(Ph)3J4 (14.5 mg, 6.2 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 15.0 mg. MS: 481.2 (M+H+); H1 NMR (DMSO-de): £(ppm) 0.52-0.74 (m, 4H), 1.88-2.18 (m, 3H), 2.78-2.89 (m, IH), 3.42- 3.74 (m, 2H), 4.78-5.13 (m, 2H), 5.16-5.29 (m, IH), 6.78-7.09 (m, 2H), 7.24-7.40 (m, 2H), 7.48+7.58 (m, IH), 7.67-7.96 (m, 6H), 8.04-8.10 (s, IH), 8.49-8.58 (m, IH). Example 2
2-(4'-Cyclopropylcarbamoylmethyl-biphenyl-4-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4002)
2-(4-Bromo-phenyl)-N-cyclopropyl-acetamide (4-Bromo-phenyl)-acetic acid (632.3 mg, 2.9 mmol) and DCC (609.2 mg, 3.0 mmol) were dissolved in dichloromethane (15 rnL) and stirred at ambient temperature for 5 minutes. Then cyclopropylamine (204.5 μL, 3.0 mmol) was added, and the reaction was stirred at ambient temperature overnight. The reaction was filtered, and the solvent was removed. The resulting mixture was redissolved in DMF (10 mL) and purified by reverse phase HPLC to give the desired product.
4-Azido-l-(4-bromo-phenyl)-butan-l-one.
A solution of l-(4-bromo-phenyl)-4-chloro-butan-l-one (2.6 Ig, 10 mmol) in DMSO (10 mL) was treated with NaI (100 mg) and NaN3 (3 eq., 2g). The mixture was heated to 60 0C overnight and then cooled. Water (30 mL) was added and the solution extracted with EtOAc (2x, 20 mL). The organics were washed with brine (Ix), dried (Na2SO4) and the solvents removed. MS: 268 (M+H+).
5-(4-Bromo-phenyl)-3,4-dihydro-2H-pyrrole.
A suspension of 4-azido-l-(4-bromo-phenyl)-butan-l-one (2.7g, 10 mmol) in hexanes (50 mL) was treated with triphenyl phosphine (leq., 2.62g) and stirred at room temperature overnight. The suspension was filtered, and washed with cold Et2O. The ether phase was diluted with 1 volume of hexanes and filtered. The organic phase was stripped of solvents and the crude product used directly in the next reaction. MS: 224 (M+H+).
2-(4-Bromo-phenyl)-pyrrolidine.
5-(4-Bromo-phenyl)-3,4-dihydro-2H-pyrrole (10 mmol) was dissolved in MeOH (w/ 20% HOAc, 5 mL) and cooled to -40 0C. NaBH4 (2 eq, 760 mg) was added and the mixture warmed to room temperature. After 2 hrs the reaction was acidified with HCl (2M, 50 mL) extracted with ether (2x 50 mL), the aqueous layer was basified with NaOH (2M in water, 100 mL) and extracted with EtOAc (2x 50 mL). The organic phase was dried with Na2SO4 and concentrated to an oil. MS: 226 (M+H+). 2-(4-Bromo-phenyl)-pyrrolidine-l-carboxylic acid benzyl ester.
A solution of 5-(4-bromo-phenyl)-3,4-dihydro-2H-pyrrole (661 mg, 3 mmol) in DMF (15 niL) at 0 0C was treated with DIPEA (1.5 eq., 781 μL) then carbonylbenzyloxychloride (1.3 eq., 540 μL). After 2 hours the solvents were removed the crude mixture was dissolved in DMF, acidified with 0.1% TFA and purified on reversed phase HPLC to give the product. MS: 360 (M+H+).
N-Cyclopr opyl-2- [4-(4,4,5,5-tetramethyl- [ 1 ,3,2] dioxaborolan-2-yl)-phenyl] -acetamide
A solution of 4,4,5,5,4>,4>,5>,5>-octamethyl-[2,2']bi[[l,3,2]dioxaborolanyl] (3.7877 g, 14.92 mmol), 2-(4-bromo-phenyl)-N-cyclopropyl-acetamide (1.2612 g, 4.96 mmol), potassium acetate (1.4608 g, 14.88 mmol), and Pd(PPh3)2Cl2 (0.3490 g, 10.0 mol%) in DMSO (30 mL) was degassed and heated to 800C overnight in a sealed vial. The reaction was cooled, and distilled water and brine were added. The mixture was centrifuged, and the liquid was decanted. The resulting solid was purified by silica gel chromatography to give the desired product. 2-(4'-Cyclopropylcarbamoylmethyl-biphenyl-4-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4002)
A solution ofN-cyclopropyl-2-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl] -acetamide (66.4 mg, 0.22 mmol), 2-(4-bromo-phenyl)-pyrrolidine-l-carboxylic acid benzyl ester (84.0 mg, 0.23 mmol), and Pd[P(Ph)3]4 (12.4 mg, 4.6 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 44.9 mg. MS: 455.2 (M+H+); H1 NMR (DMSO- d6): £(ppm) 0.37-0.46 (m, 2H), 0.58-0.68 (m, 2H), 1.68-1.93 (m, 3H), 2.20-2.46 (m, IH), 2.56-2.68 (m, IH), 3.34-3.42 (s, 2H), 3.48-3.73 (m2H), 4.81-5.12 (m, 3H), 6.80-6.90 (m, IH), 7.05-7.40 (m, 8H), 7.49-7.63 (m, 4H), 8.13-8.20 (d, IH).
Example 3
(S)-2-[6-(3-Cyclopropylcarbamoylmethyl-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine- 1-carboxylic acid benzyl ester (Compound 4003)
2-(3-Bromo-phenyl)-N-cyclopropyl-acetamide (3-Bromo-phenyl)-acetic acid (636.0 mg, 3.0 mmol) and DCC (608.2 mg, 2.9 mmol) were dissolved in dichloromethane (15 mL) and stirred at ambient temperature for 5 minutes. Then cyclopropylamine (204.5 μL, 3.0 mmol) was added, and the reaction was stirred at ambient temperature overnight. The reaction was filtered, and the solvent was removed. The resulting mixture was redissolved in DMF (10 mL) and purified by reverse phase HPLC to give the desired product.
(S)-2-[6-(3-Cyclopropylcarbamoylmethyl-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine- 1-carboxylic acid benzyl ester (Compound 4003)
A solution of (S)-2-[5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- benzoimidazol-2-yl]-pyrrolidine- 1-carboxylic acid benzyl ester (90 mg, 0.20 mmol), 2-(3- bromo-phenyl)-N-cyclopropyl-acetamide (51.8 mg, 0.20 mmol), and Pd[P(Ph)3J4 (13.5 mg, 5.8 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 15.0 mg. MS: 495.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.30-0.55 (m, 2H), 0.53-0.78 (m, 2H), 1.92-2.21 (m, 3H), 2.55-2.68 (m, IH), 3.55-3.80 (m, 2H), 4.81-5.19 (m, 2H), 5.19-5.32 (m, IH), 7.02- 7.13 (m, 2H), 7.21-7.89 (m, 10H), 8.16-8.23 (m, IH). Example 4
(S)-2-[4'-(Cyclopropanecarbonyl-amino)-biphenyl-3-ylethynyl]-pyrrolidine-l- carboxylic acid benzyl ester (Compound 4004)
A solution of (S)-2-(3-boronic acid-phenylethynyl)-pyrrolidine- 1-carboxylic acid benzyl ester (62.5 mg, 0.18 mmol), cyclopropanecarboxylic acid (4-bromo-phenyl)-amide (Example 58, 43.5 mg, 0.18 mmol), and Pd[P(Ph)3]4 (12.7 mg, 6.1 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (1.6 mL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 21.8 mg. MS: 465.2 (M+H+); H1 NMR (DMSO- d6): £(ppm) 0.73-0.85 (m, 4H), 1.70-2.30 (m, 5H), 4.71-4.83 (m, IH), 4.80-5.31 (m, 2H), 7.17-7.71 (m, 13H), 10.24-10.31 (2, IH).
Example 5
(S)-2-[6-(lH-Indol-5-yl)-benzothiazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester
(Compound 4005)
From 1 eq. lH-indole 5-boronic acid following General Procedure D. Yield 44 mg. MS: 454.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 11.1 (s, IH), 8.3 (s, IH), 7.9-7.7 (m, 3H), 7.5-7.3 (m, 6H), 7.1-6.9 (m, 2H), 6.5 (s, IH), 5.3 (m, IH), 5.2-4.8 (m, 3H), 3.6-3.5 (m, 4H), 2.39 (m, IH), 2.12-1.98 (m, 3H).
Example 6
(S) -4-[5-(4-Cyclopropylcarbamoyl-phenyl)-lH-benzoimidazol-2-yl]-2-pyridin-4-yl- thiazolidine-3-carboxylic acid benzyl ester (Compound 4006)
(S)- 4-(2-Amino-4-bromo-phenylcarbamoyl)-2-pyridin-4-yl-thiazolidine-3-carboxylic acid benzyl ester.
2-Pyridin-4-yl-thiazolidine-3,4-dicarboxylic acid 3 -benzyl ester (172 mg) was dissolved in DMF (15 niL) and treated with PyBrOP (1.1 eq. 256 mg) and DIPEA (2.1 eq, 200 μL) and stirred for 15 minutes. Then 4-bromo-benzene-l,2-di amine (1 eq, 102 mg) was added and the mixture stirred at ambient temperature overnight. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. MS: 513.5 (M+H+) (S)- 4-(5-Bromo-lH-benzoimidazol-2-yl)-2-pyridin-4-yl-thiazolidine-3-carboxylic acid benzyl ester.
(S)- 4-(2-Amino-4-bromo-phenylcarbamoyl)-2-pyridin-4-yl-thiazolidine-3- carboxylic acid benzyl ester (from above) was dissolved in HOAc (10 mL) and heated to 90 0C for 3 hours. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. MS: 495.5 (M+H+).
(S) -4-[5-(4-Cyclopropylcarbamoyl-phenyl)-lH-benzoimidazol-2-yl]-2-pyridin-4-yl- thiazolidine-3-carboxylic acid benzyl ester (Compound 4006).
A solution of (S)- 4-(5-bromo-lH-benzoimidazol-2-yl)-2-pyridin-4-yl-thiazolidine- 3-carboxylic acid benzyl ester (49.5 mg, 0.1 mmol), N-cyclopropyl-4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-benzamide (Example 10, 29mg, 1 eq), Pd[P(Ph)3]4 (5 mol %, 11 mg), in methanol (2 mL), NaHCO3 (sat. aq., 300 μL) and DMF (400 μL) was degassed and heated to 70 0C overnight in a sealed vial. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. Yield 33.5 mg. MS: 576.5 (M + H+); H'-NMR (DMSO-d6): £(ppm) 8.8-8.4 (m, 3H), 8.0-7.6 (m, 6H), 7.3-6.9 (m, 5H), 6.4-6.0 (m, 2H), 5.2-4.8 (m, 3H), 3.7 (m, 2H), 3.4 (m, 2H), 2.87 (m, IH), 0.7-0.6 (m, 4H).
Example 7
(S)-2-(6-Phenyl-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4007)
From 1 eq of bromo-benzene following General Procedure A. Yield 14.0 mg. MS: 398.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 7.9-7.7 (m, 5H), 7.48 (s, 2H), 7.3 (m, 3H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 8 (S)-2- [6-(4- Amino-phenyl)- lH-benzoimidazol-2-yl] -pyrrolidine- 1-carboxylic acid benzyl ester (Compound 4008)
From 1 eq. of 4-bromo-phenylamine following General Procedure A. Yield 6.6 mg. MS: 412.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 7.85-7.6 (m, 4H), 7.35 (m, 3H), 7.1 (m, 2H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H). Example 9
2-[3'-(Cyclopropanecarbonyl-amino)-biphenyl-4-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4009)
Cyclopropanecarboxylic acid [3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl] -amide A solution of 4,4,5,5,4>,4>,5',5'-octamethyl-[2,2>]bi[[l,3,2]dioxaborolanyl] (3.9783 g,
15.67 mmol), cyclopropanecarboxylic acid (3-bromo-phenyl)-amide (Example 37, 1.2515 g, 5.21 mmol), potassium acetate (1.5250 g, 15.54 mmol), and Pd(PPh3)2Cl2 (0.3646 g, 10.0 mol%) in DMSO (30 mL) was degassed and heated to 800C overnight in a sealed vial. The reaction was cooled, and distilled water and brine were added. The mixture was centrifuged, and the liquid was decanted. The resulting solid was purified by silica gel chromatography to give the desired product.
2-[3'-(Cyclopropanecarbonyl-amino)-biphenyl-4-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4009)
A solution of cyclopropanecarboxylic acid [3-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenyl]-amide (65.5 mg, 0.23 mmol), 2-(4-bromo-phenyl)- pyrrolidine- 1-carboxylic acid benzyl ester (83.3 mg, 0.23 mmol), and Pd[P(Ph)3J4 (12.4 mg, 4.6 mol %) in methanol (2 niL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 14.2 mg. MS: 441.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.75-0.90 (m, 4H), 1.68-1.94 (m, 4H), 2.21-2.45 (m, IH), 3.47-3.74 (m, 2H), 4.80-5.13 (m, 3H), 6.78-6.89 (m, IH), 7.05-7.59 (m, HH), 7.84-7.97 (d, IH), 10.22-10.33 (s, IH).
Example 10
(S)-2-[6-(4-Cyclopropylcarbamoyl-phenyl)-lH-benzoimidazol-2-yl]-2,3-dihydro- indole-1-carboxylic acid benzyl ester (Compound 4010)
4-Bromo-N-cyclopropyl-benzamide
4-Bromo-benzoic acid (2.5116 g, 12.5 mmol) and HATU (5.2213 g, 13.7 mmol) were dissolved in DMF (40 mL). DIPEA (4.572 mL, 26.2 mmol) was added, and the mixture was allowed to stir at ambient temperature for 15 minutes. Then eye lopropyl amine (0.866 mL, 12.5 mmol) was added, and the reaction was stirred at ambient temperature overnight. The solvent was removed, and the crude was purified via silica gel chromatography to give the desired product.
N-Cyclopropyl-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide
A solution of 4,4,5,5,4>,4>,5>,5>-octamethyl-[2,2']bi[[l,3,2]dioxaborolanyl] (3.9837 g, 15.67 mmol), 4-bromo-N-cyclopropyl-benzamide (1.2516 g, 5.21 mmol), potassium acetate (1.5353 g, 15.64 mmol), and Pd(PPh3)2Cl2 (0.3677 g, 10.0 mol%) in DMSO (30 mL) was degassed and heated to 800C overnight in a sealed vial. The reaction was cooled, and distilled water and brine were added. The mixture was centrifuged, and the liquid was decanted. The resulting solid was purified by silica gel chromatography to give the desired product.
(S)-2-(2-Amino-4-bromo-phenylcarbamoyl)-2,3-dihydro-indole-l-carboxylic acid benzyl ester & (S)-2-(2-Amino-5-bromo-phenylcarbamoyl)-2,3-dihydro-indole-l- carboxylic acid benzyl ester
(S)-2,3-Dihydro-indole-l,2-dicarboxylic acid 1-benzyl ester (394.7 mg, 1.33 mmol) was dissolved in DMF (10 mL). DIPEA (465 μL, 2.67 mmol) was added followed by HATU (504.8 mg, 1.33 mmol). The reaction was stirred at ambient temperature for 15 minutes. Then 4-bromo-benzene-l,2-diamine (250.1 mg, 1.34 mmol) was added, and the reaction was stirred at ambient temperature for 1 hour. The reaction was filtered and purified by reverse phase HPLC.
(S)-2-(6-Bromo-lH-benzoimidazol-2-yl)-2,3-dihydro-indole-l-carboxylic acid benzyl ester A solution of (S)-2-(2-amino-4-bromo-phenylcarbamoyl)-2,3-dihydro-indole-l- carboxylic acid benzyl ester and (S)-2-(2-Amino-5-bromo-phenylcarbamoyl)-2,3-dihydro- indole-1-carboxylic acid benzyl ester (619 mg, 1.33 mmol) in glacial acetic acid (5 mL) was heated to 1100C in a sealed vial for 2.5 hours. The acetic acid was removed, and the resulting mixture was filtered and purified by reverse phase HPLC to give the desired product.
(S)-2-[6-(4-Cyclopropylcarbamoyl-phenyl)-lH-benzoimidazol-2-yl]-2,3-dihydro- indole-1-carboxylic acid benzyl ester (Compound 4010)
A solution of N-cyclopropyl-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- benzamide (75.9 mg, 0.26 mmol), (S)-2-(6-bromo-lH-benzoimidazol-2-yl)-2,3-dihydro- indole- 1-carboxylic acid benzyl ester (60 mg, 0.13 mmol), and Pd[P(Ph)3J4 (8.3 mg, 5.4 mol%) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. The product was then converted to the HCl salt. After dissolving the product in a minimum amount of acetonitrile and cooling the solution in dry ice, 2.0M HCl in diethyl ether was added until precipitate crashed out of solution. The mixture was centrifuged, and the liquid was decanted. Additional cold diethyl ether was added, and the mixture was again centrifuged and the liquid decanted. The resulting solid was dried to give the HCl salt of the desired product. Yield 7.9 mg. MS: 529.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.55-0.77 (m, 4H), 2.80- 2.93 (m, IH), 3.32-3.45 (m, IH), 3.75-3.90 (m, IH), 5.96-6.08 (m, IH), 6.87-7.33 (m, 6H), 7.68-8.00 (m, 8H), 8.48-8.54 (d, IH).
Example 11
(S)-2-(6-Naphthalen-2-yl-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4011) From 1 eq. of 2-Bromo-naphthalene following General Procedure A. Yield 5.4 mg.
MS: 448.5 (M-NHCOCH3); H'-NMR (DMSO-d6): £(ppm) 8.2(s, IH), 8.0-7.6 (m, 7H), 7.5 (m, 2H), 7.3 (m, 2H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 12
(S)-2-[6-(5-Nitro-furan-2-yl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4012)
From 1 eq. of 2-Bromo-5-nitro-furan following General Procedure A. Yield 8 mg. MS: 433.4 (M+H+); H!-NMR (DMSO-d6): £(ppm) 8.1-7.7 (m, 3H), 7.5 (m, IH), 7.3 (m, 3H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 13 (S)-2-(6-Quinolin-3-yl-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4013)
From 1 eq. of 3-Bromo-quinoline following General Procedure A. Yield 24 mg. MS: 449.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 9.5 (m, IH), 9.1 (m, IH), 8.3-7.7 (m, 6H), 7.5 (m, IH), 7.3 (m, 3H), 7.0-6.8 (m, 2H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 14
(S)-2-[6-(lH-Indol-7-yl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4014)
From 1 eq. of 7-Bromo-lH-indole following General Procedure A. Yield 16 mg. MS: 437.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 7.9-7.5 (s, 5H), 7.3 (m, 4H), 7.1-6.8 (m, 4H), 6.5 (m, IH), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 15
(S)-2-[6-(4-Trifluoromethyl-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4015) From 1 eq. of 4- trifluoromethyl phenylboronic acid following General Procedure B.
Yield 25 mg. MS: 466.5 (M+H+); H'-NMR (DMSO-d6): £(ppm) 8.2-8.4 (m, 4H), 7.9 (m, IH), 7.7 (m, IH), 7.75 (s, IH), 7.3 (m, 3H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.81 (s, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H). Example 16
(S)-2-[6-(3-Methoxy-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4016)
From 1 eq. of 3-Methoxy-phenylboronic acid following General Procedure B. Yield 24 mg. MS: 428.5 ( (M+H+); H'-NMR (DMSO-d6): £(ppm) 7.9-7.7 (m, 5H), 7.4-7.2 (m, 5H), 7.0-6.8 (m, 2H), 5.2-4.8 (m, 3H), 3.84 (s, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 17
(S)-2- [6-(2,4-Dimethoxy-phenyl)- lH-benzoimidazol-2-yl] -pyrrolidine- 1-carboxylic acid benzyl ester (Compound 4017)
From 1 eq. of 2,4-Dimethoxy-phenyl-lboronic acid following General Procedure B. Yield 15 mg. MS: 458.5 (M+H+); H'-NMR (DMSO-d6): £(ppm) 7.7 (m, 3H), 7.5 (m, IH), 7.4-7.25 (m, 4H), 7.0-6.8 (m, 3H), 6.65 (m, 2H), 5.2-4.8 (m, 3H), 3.81 (s, 3H), 3.77 (s, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 18
(S)-2-[6-(lH-Indol-6-yl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4018)
From 1 eq. of lH-indole 6-lboronic acid following General Procedure B. Yield 36 mg. MS: 437.5 (M-NHCOCH3); H!-NMR (DMSO-d6): £(ppm) 7.9-7.6 (m, 5H), 7.3 (m, 4H), 7.0-6.8 (m, 2H), 6.5 (m, IH), 5.2-4.8 (m, 3H), 3.81 (s, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 19
(S)-2-[6-(4-Cyclopropylcarbamoyl-phenyl)-benzooxazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4019) From 1 eq. of N-cyclopropyl-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- benzamide (Example 10) following General Procedure C. Yield 22 mg. MS: 482.5 (M- NHCOCH3); H1 -NMR (DMSO-d6): £(ppm) 8.4 (m, IH), 8.0 (m, IH), 7.9-7.6 (m, 5H), 7.3 (m, 2H), 7.1-6.8 (m, 2H), 5.2-4.8 (m, 3H), 2.8 (m, IH), 2.42 (m, IH), 2.02 (m, 3H), 0.7-0.6 (m, 4H) Example 20
(S)-2-[6-(4-Cyclopropylcarbamoyl-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l- carboxylic acid benzyl ester ( Compound 4020)
A solution of (S)-2-[5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- benzoimidazol-2-yl] -pyrrolidine- 1-carboxylic acid benzyl ester (93.5 mg, 0.33 mmol), 4- bromo-N-cyclopropyl-benzamide (Example 10, 137.4 mg, 0.34 mmol), and Pd[P(Ph)3]4 (19.2 mg, 5.1 mol %) in methanol (4 mL), NaHCO3 (sat. aq., 600 μL), and DMF (800 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. The product was then converted to the HCl salt. After dissolving the product in a minimum amount of acetonitrile and cooling the solution in dry ice, 2.0M HCl in diethyl ether was added until precipitate crashed out of solution. The mixture was centrifuged, and the liquid was decanted. Additional cold diethyl ether was added, and the mixture was again centrifuged and the liquid decanted. The resulting solid was dried to give the HCl salt of the desired product. Yield 32.2 mg. MS: 481.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.54-0.76 (m, 4H), 1.92-2.27 (m, 3H), 2.81-2.93 (m, IH), 3.38-3.85 (m, 2H), 4.80-5.17 (m, 2H), 5.25-5.40 (m, IH), 6.83-7.10 (m, 2H), 7.26-7.43 (m, 2H), 7.74-8.03 (m, 8H), 8.49-8.57 (m, IH).
Example 21
(S)-2-[6-(4-Cyclopropylcarbamoylmethyl-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine- 1-carboxylic acid benzyl ester (Compound 4021)
A solution of (S)-2-[5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- benzoimidazol-2-yl]-pyrrolidine- 1-carboxylic acid benzyl ester (90 mg, 0.20 mmol), 2-(4- bromo-phenyl)-N-cyclopropyl-acetamide (Example 2, 51.0 mg, 0.20 mmol), and Pd[P(Ph)3]4 (14.3 mg, 6.2 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 15.0 mg. MS: 495.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.35-0.45 (m, 2H), 0.53-0.67 (m, 2H), 1.90-2.20 (m, 3H), 2.55-2.69 (m, IH), 3.45-3.81 (m, 2H), 4.79-5.18 (m, 2H), 5.18- 5.32 (m, IH), 6.80-7.12 (m, 2H), 7.24-7.41 (m, 4H), 7.50-7.97 (m, 6H), 8.11-8.22 (m, IH). Example 22
(S)-2-[6-(4-Cyclopropylcarbamoyl-phenyl)-benzothazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4022)
From 1 eq. of N-cyclopropyl-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- benzamide (Example 10) following General Procedure D. Yield 6.5 mg. MS: 498 (M-
NHCOCH3); H!-NMR (DMSO-d6): £(ppm) 8.5 (m, IH), 8.4 (m, IH), 8.0-7.8 (m, 6H), 7.3 (m, 2H), 7.1-6.8 (m, 2H), 5.3 (m, IH), 5.2-4.8 (m, 2H), 3.6 (m, 4H), 2.8 (m, IH), 2.42 (m, IH), 1.98 (m, 3H), 0.7-0.6 (m, 4H).
Example 23 2-{3'-[(Cyclopropanecarbonyl-amino)-methyl]-biphenyl-4-yl}-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4023)
Cyclopropanecarboxylic acid 3-bromo-benzylamide
3-Bromo-benzylamine hydrochloride (437.3 mg, 2.0 mmol) was dissolved in dichloromethane (15 mL), and the solution was cooled to 00C. DIPEA (688.0 μL, 3.9 mmol) was then added, and the reaction was stirred at 00C for 5 minutes. Then cyclopropanecarbonyl chloride (180.0 μL, 2.3 mmol) was added, and the reaction was stirred at 00C for 20 minutes. The reaction was quenched with distilled water, and the solvents were removed. The resulting mixture was redissolved in DMF (10 mL) and purified by reverse phase HPLC to give the desired product. Cyclopropanecarboxylic acid 3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- benzylamide
A solution of 4,4,5,5,4>,4>,5',5'-octamethyl-[2,2>]bi[[l,3,2]dioxaborolanyl] (3.7925 g, 14.93 mmol), cyclopropanecarboxylic acid 3-bromo-benzylamide (1.2595 g, 4.96 mmol), potassium acetate (1.4632 g, 14.91 mmol), and Pd(PPh3)2Cl2 (0.3452 g, 9.9 mol%) in DMSO (30 mL) was degassed and heated to 800C overnight in a sealed vial. The reaction was cooled, and distilled water and brine were added. The mixture was centrifuged, and the liquid was decanted. The resulting solid was purified by silica gel chromatography to give the desired product. 2-{3'-[(Cyclopropanecarbonyl-amino)-methyl]-biphenyl-4-yl}-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4023)
A solution of cyclopropanecarboxylic acid 3-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-benzylamide (66.4 mg, 0.22 mmol), 2-(4-bromo-phenyl)- pyrrolidine- 1-carboxylic acid benzyl ester (83.1 mg, 0.23 mmol), and Pd[P(Ph)3]4 (12.7 mg, 4.8 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 30.0 mg. MS: 455.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.60-0.79 (m, 4H), 1.56-1.96 (m, 4H), 2.20-2.47 (m, IH), 3.47-3.75 (m, 2H), 4.29-4.40 (s, 2H), 4.80-5.12 (m, 3H), 6.79-6.90 (m, IH), 7.05- 7.61 (m, 12H), 8.53-8.67 (m, IH).
Example 24
(S)-2-(4'-Cyclopropylcarbamoylmethyl-biphenyl-3-ylethynyl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4024) A solution of (S)-2-(3-boronic acid-phenylethynyl)-pyrrolidine- 1-carboxylic acid benzyl ester (62.5 mg, 0.18 mmol), 2-(4-bromo-phenyl)-N-cyclopropyl-acetamide (Example 2, 45.8 mg, 0.18 mmol), and Pd[P(Ph)3]4 (11.1 mg, 5.4 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (1.6 mL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 23.4 mg. MS: 479.6 (M+H+); H1 NMR (DMSO-d6): δ (ppm) 0.36-0.44 (m, 2H), 0.57-0.66 (m, 2H), 1.86-2.30 (m, 4H), 2.54-2.65 (m, IH), 4.72- 4.84 (m, IH), 4.98-5.31 (m, 2H), 7.14-7.68 (m, 13H), 8.11-8.17 (m, IH).
Example 25
(S)-2-(6-Pyridin-2-yl-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4025)
From 1 eq. of 2-bromo-pyridine following General Procedure A. Yield 41 mg. MS: 399.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 8.7 (m, IH), 8.4-7.8 (m, 3H), 7.47 (s, IH), 7.3 (m, 3H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H). Example 26
2-[4'-(Cyclopropanecarbonyl-amino)-biphenyl-4-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4026)
Cyclopropanecarboxylic acid [4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenyl] -amide
A solution of 4,4,5,5,4>,4>,5',5'-octamethyl-[2,2>]bi[[l,3,2]dioxaborolanyl] (3.9704 g, 15.64 mmol), cyclopropanecarboxylic acid (4-bromo-phenyl)-amide( Example 58, 1.2498 g, 5.21 mmol), potassium acetate (1.5272 g, 15.56 mmol), and Pd(PPhS)2Cl2 (0.3639 g, 10.0 mol%) in DMSO (30 mL) was degassed and heated to 800C overnight in a sealed vial. The reaction was cooled, and distilled water and brine were added. The mixture was centrifuged, and the liquid was decanted. The resulting solid was purified by silica gel chromatography to give the desired product.
2-[4'-(Cyclopropanecarbonyl-amino)-biphenyl-4-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4026) A solution of cyclopropanecarboxylic acid [4-(4,4,5,5-tetramethyl-
[l,3,2]dioxaborolan-2-yl)-phenyl]-amide (66.2 mg, 0.23 mmol), 2-(4-bromo-phenyl)- pyrrolidine-1-carboxylic acid benzyl ester (82.0 mg, 0.23 mmol), and Pd[P(Ph)3J4 (12.3 mg, 4.6 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 22.3 mg. MS: 441.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.75-0.86 (m, 4H), 1.68-1.94 (m, 4H), 2.21-2.42 (m, IH), 3.48-3.73 (m, 2H), 4.80-5.12 (m, 3H), 6.81-6.89 (m, IH), 7.06-7.40 (m, 6H), 7.50- 7.72 (m, 6H), 10.24-10.30 (s, IH).
Example 27 2-(3'-Cyclopropylcarbamoyl-biphenyl-4-yl)-pyrrolidine-l-carboxylic acid benzyl ester
(Compound 4027)
N-Cyclopropyl-3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide
A solution of 4,4,5,5,4>,4>,5>,5>-octamethyl-[2,2']bi[[l,3,2]dioxaborolanyl] (3.9706 g, 15.64 mmol), 3-bromo-N-cyclopropyl-benzamide (Example 1, 1.2463 g, 5.19 mmol), potassium acetate (1.5394 g, 15.69 mmol), and Pd(PPh3)2Cl2 (0.3645 g, 10.0 mol%) in
DMSO (30 mL) was degassed and heated to 800C overnight in a sealed vial. The reaction was cooled, and distilled water and brine were added. The mixture was centrifuged, and the liquid was decanted. The resulting solid was purified by silica gel chromatography to give the desired product.
2-(3'-Cyclopropylcarbamoyl-biphenyl-4-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4027)
A solution of N-cyclopropyl-3-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- benzamide (65.0 mg, 0.23 mmol), 2-(4-bromo-phenyl)-pyrrolidine-l-carboxylic acid benzyl ester (82.6 mg, 0.23 mmol), and Pd[P(Ph)3J4 (12.7 mg, 4.9 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 20.5 mg. MS: 441.2 (M+H+); H1 NMR (DMSO-d6): δ (ppm) 0.54-0.77 (m, 4H), 1.69-1.93 (m, 3H), 2.22-2.45 (m, IH), 2.80-2.91 (m, IH), 3.48- 3.74 (m, 2H), 4.82-5.14 (m, 3H), 6.81-6.95 (m, IH), 7.05-7.85 (m, HH), 7.98-8.08 (m, IH), 8.47-8.56 (m, IH). Example 28
(S)-2-[6-(4-Nitro-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4028)
From 1 eq of 4-bromo nitrobenzene following General Procedure A. Yield 17 mg. MS: 443.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 8.3 (m, IH), 8.0-7.7 (m, 5H), 7.3 (m, 3H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 29
(S)-2-(6-Thiophen-2-yl-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4029)
From 1 eq. of 2-bromo-thiophene following General Procedure A. Yield 30 mg. MS: 404.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 7.9-7.7 (m, 4H), 7.6 (m, 2H), 7.3 (m, 2H), 7.1 (m, IH), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H). Example 30
(S)-2-(6-Furan-2-yl-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester
(Compound 4030)
From 1 eq. of furan-2-yl-lboronic acid following General Procedure B. Yield 5.4 mg. MS: 388.4 (M+H+); H!-NMR (DMSO-d6): £(ppm) 7.9-7.7 (m, 4H), 7.3 (m, 3H), 7.1 (m, 2H), 7.0-6.8 (m, 3H), 6.6 (m, IH), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 31
(S)-2-[6-(3-Cyano-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4031)
From 1 eq. of benzonitrile-3-boronic acid following General Procedure B. Yield 15 mg. MS: 423.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 8.02-7.8 (m, 8H), 7.37 (m, 3H), 7.0-6.8 (m, 2H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 32 (S)-2-(6-Benzo[l,3]dioxol-5-yl-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4032)
From 1 eq. of benzo[l,3]dioxol-5-yl-boronic acid following General Procedure B. Yield 15 mg. MS: 442.5 (M+H+); H'-NMR (DMSO-d6): £(ppm) 7.8-7.7 (m, 3H), 7.4-6.8 (m, 8H), 6.07 (s, 2H) 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 33
(S)-2-[6-(7-Nitro-lH-indol-5-yl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4033)
From 1 eq. of 5-bromo-7-nitro-lH-indole following General Procedure A. Yield 22 mg. MS: 482.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 8.43 (s, IH), 8.35 (s, IH), 8.0-7.7 (m, 4H), 7.6 (m, IH), 7.3 (m, 3H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H). Example 34
(S)-2-[6-(4-Ureido-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4034)
From 1 eq. of (4-bromo-phenyl)-urea following General Procedure A. Yield 48 mg. MS: 456.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 7.9-7.3 (m, 1 IH), 7.0-6.8 (m, 3H), 6.4 (br s, IH), 6.1 (IH, br s), 5.2-4.8 (m, 3H), 3.81 (s, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 35
(S)-2-[6-(lH-Indol-5-yl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4035)
From 1 eq. of lH-indole 5-boronic acid following General Procedure A. Yield 30 mg. MS: 437.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 7.9-7.7 (m, 5H), 7.3 (m, 5H), 7.0- 6.8 (m, 2H), 6.5 (m, IH), 5.2-4.8 (m, 3H), 3.76 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 3.53 (m, 3H), 2.02 (m, 4H). Example 36
(S)-2-[6-(4-Methanesulfonyl-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4036)
From 1 eq. of 4-methanesulfonyl-phenyl-boronic acid following General Procedure B. Yield 39 mg. MS: 476.6 (M+H+); H!-NMR (DMSO-d6): £(ppm) 8.0 (m, 5H), 7.8 (m, 2H), 7.3 (m, 3H), 7.0-6.8 (m, 2H), 5.2-4.8 (m, 3H) 3.70 (m, IH), 3.55 (m, IH), 3.28 (s, 3H), 2.02 (m, 4H).
Example 37
(S)-2-{6-[3-(Cyclopropanecarbonyl-amino)-phenyl]-lH-benzoimidazol-2-yl}- pyrrolidine-1-carboxylic acid benzyl ester (Compound 4037) Cyclopropanecarboxylic acid (3-bromo-phenyl)-amide
3-Bromo-phenylamine (0.431 mL, 4.0 mmol) was dissolved in dichloromethane (30 mL), and the solution was cooled to 00C. DIPEA (1.38 mL, 7.9 mmol) was then added, and the reaction was stirred at 00C for 5 minutes. Then cyclopropanecarbonyl chloride (0.315 mL, 4.0 mmol) was added, and the reaction was stirred at 00C for 20 minutes. The reaction was quenched with distilled water, and the solvents were removed. The resulting mixture was redissolved in DMF (10 niL) and purified by reverse phase HPLC to give the desired product.
(S)-2-{6-[3-(Cyclopropanecarbonyl-amino)-phenyl]-lH-benzoimidazol-2-yl}- pyrrolidine-1-carboxylic acid benzyl ester (Compound 4037) A solution of (S)-2-[5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (90 mg, 0.20 mmol), cyclopropanecarboxylic acid (3-bromo-phenyl)-amide (48.6 mg, 0.20 mmol), and Pd[P(Ph)3J4 (13.5 mg, 5.8 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 15.0 mg. MS: 481.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.74-0.90 (m, 4H), 1.72-1.87 (m, IH), 1.90-2.21 (m, 3H), 3.45-3.78 (m, 2H), 4.79-5.16 (m, 2H), 5.19-5.32 (m, IH), 6.80- 7.12 (m, 2H), 7.35-8.06 (m, 10H), 10.28-10.37 (s, IH).
Example 38 (S)-2-(6- {4- [(Cyclopr opanecarbonyl-amino)-methyl] -phenyl}- lH-benzoimidazol-2-yl)- pyrrolidine-1-carboxylic acid benzyl ester (Compound 4038)
Cyclopropanecarboxylic acid 4-bromo-benzylamide
4-Bromo-benzylamine hydrochloride (367.8 mg, 1.7 mmol) was dissolved in dichloromethane (15 mL), and the solution was cooled to 00C. DIPEA (380 μL, 2.2 mmol) was then added, and the reaction was stirred at 00C for 5 minutes. Then cyclopropanecarbonyl chloride (180 μL, 2.3 mmol) was added, and the reaction was stirred at 00C for 20 minutes. The reaction was quenched with distilled water, and the solvents were removed. The resulting mixture was redissolved in DMF (10 mL) and purified by reverse phase HPLC to give the desired product. (S)-2-(5- {4- [(Cyclopr opanecarbonyl-amino)-methyl] -phenyl}- lH-benzoimidazol-2-yl)- pyrrolidine-1-carboxylic acid benzyl ester (Compound 4038)
A solution of (S)-2-[5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- benzoimidazol-2-yl] -pyrrolidine- 1-carboxylic acid benzyl ester (181.2 mg, 0.41 mmol), cyclopropanecarboxylic acid 4-bromo-benzylamide (103.1 mg, 0.41 mmol), and Pd[P(Ph)3]4 (24.2 mg, 5.2 mol %) in methanol (4 mL), NaHCO3 (sat. aq., 600 μL), and DMF (800 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. The product was then converted to the HCl salt according to the procedure for GL101520. Yield 15.0 mg. MS: 495.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.58-0.80 (m, 4H), 1.52-1.69 (m, IH), 1.90-2.21 (m, 3H), 3.45-3.65 (m, IH), 4.20-4.48 (m, 2H), 4.80-5.18 (m, 2H), 5.18- 5.31 (m, IH), 6.81-7.98 (m, 12H), 8.50-8.64 (m, IH). Example 39
(S)-2-[6-(lH-Indol-5-yl)-benzooxazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester
(Compound 4039)
From 1 eq. lH-indole 5-boronic acid following General Procedure C. Yield 13.9 mg. MS: 438.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 11.1 (s, IH), 7.9-7.6 (m, 6H), 7.5-7.3 (m, 7H), 7.1-6.9 (m, 3H), 6.5 (s, IH), 5.2-4.8 (m, 3H), 3.6-3.5 (m, 4H), 2.39 (m, IH), 2.12 (m, 3H).
Example 40
2-{4'-[(Cyclopropanecarbonyl-amino)-methyl]-biphenyl-4-yl}-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4040) Cyclopropanecarboxylic acid 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- benzylamide
A solution of 4,4,5,5,4>,4>,5>,5>-octamethyl-[2,2']bi[[l,3,2]dioxaborolanyl] (1.4976 g, 5.90 mmol), cyclopropanecarboxylic acid 4-bromo-benzylamide (Example 38, 0.4991 g, 1.96 mmol), potassium acetate (0.5708 g, 5.82 mmol), and Pd(PPh3)2Cl2 (0.1403 g, 10.2 mol%) in DMSO (16 mL) was degassed and heated to 800C overnight in a sealed vial. The reaction was cooled, and distilled water and brine were added. The mixture was centrifuged, and the liquid was decanted. The resulting solid was purified by silica gel chromatography to give the desired product.
2-{4'-[(Cyclopropanecarbonyl-amino)-methyl]-biphenyl-4-yl}-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4040)
A solution of cyclopropanecarboxylic acid 4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-benzylamide (66.3 mg, 0.22 mmol), 2-(4-bromo-phenyl)- pyrrolidine-1-carboxylic acid benzyl ester (82.9 mg, 0.23 mmol), and Pd[P(Ph)3]4 (12.7 mg, 5.0 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 30.4 mg. MS: 455.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.59-0.78 (m, 4H), 1.55-1.94 (m, 4H), 2.20-2.43 (m, IH), 3.48-3.75 (m, 2H), 4.23-4.36 (m, 2H), 4.78-5.12 (m, 3H), 6.78-6.89 (m, IH), 7.00- 7.65 (m, 12H), 8.51-8.66 (m, IH).
Example 41 (S)-2-{4'-[(Cyclopropanecarbonyl-amino)-methyl]-biphenyl-3-ylethynyl}-pyrrolidine-
1-carboxylic acid benzyl ester (Compound 4041)
A solution of (S)-2-(3-boronic acid-phenylethynyl)-pyrrolidine-l-carboxylic acid benzyl ester (62.5 mg, 0.18 mmol), cyclopropanecarboxylic acid 4-bromo-benzylamide (Example 38, 45.6 mg, 0.18 mmol), and Pd[P(Ph)3J4 (11.2 mg, 5.4 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 11.6 mg. MS: 479.5 (M+H+); H1 NMR (DMSO- d6): £(ppm) 0.64-0.75 (m, 4H), 1.56-1.67 (m, IH), 1.86-2.30 (m, 4H), 4.27-4.34 (d, 2H), 4.71-4.84 (m, IH), 4.96-5.31 (m, 2H), 7.08-7.67 (m, 13H), 8.52-8.62 (m, IH). Example 42
(S)-2-(6-Pyridin-4-yl-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4042)
From 1 eq. of 4-bromo-pyridine following General Procedure A. Yield 24 mg. MS: 399.5 (M+H+); M+H+); H!-NMR (DMSO-d6): £(ppm) 8.2-8.4 (m, 4H), 7.9 (m, IH), 7.7 (m, IH), 7.75 (s, IH), 7.3 (m, 3H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.81 (s, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 43
2-(3'-Cyclopropylcarbamoylmethyl-biphenyl-4-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4043) N-Cyclopr opyl-2- [3-(4,4,5,5-tetramethyl- [ 1 ,3,2] dioxaborolan-2-yl)-phenyl] -acetamide
A solution of 4,4,5,5,4>,4>,5>,5>-octamethyl-[2,2']bi[[l,3,2]dioxaborolanyl] (3.8025 g, 14.97 mmol), 2-(3-bromo-phenyl)-N-cyclopropyl-acetamide (Example 3, 0.8089 g, 3.18 mmol), potassium acetate (1.4564 g, 14.84 mmol), and Pd(PPh3)2Cl2 (0.3490 g, 15.6 mol%) in DMSO (30 mL) was degassed and heated to 800C overnight in a sealed vial. The reaction was cooled, and distilled water and brine were added. The mixture was centrifuged, and the liquid was decanted. The resulting solid was purified by silica gel chromatography to give the desired product.
2-(3'-Cyclopropylcarbamoylmethyl-biphenyl-4-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4043) A solution
Figure imgf000069_0001
pheny^-acetamide (66.1 mg, 0.22 mmol), 2-(4-bromo-phenyl)-pyrrolidine-l-carboxylic acid benzyl ester (81.8 mg, 0.23 mmol), and Pd[P(Ph)3J4 (12.8 mg, 5.0 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 37.8 mg. MS: 455.2 (M+H+); H1 NMR (DMSO- d6): £(ppm) 0.35-0.44 (m, 2H), 0.55-0.70 (m, 2H), 1.66-1.92 (m, 3H), 2.20-2.45 (m, IH), 2.53-2.65 (m, IH), 3.35-3.44 (s, 2H), 3.46-3.72 (m, 2H), 5.30-5.62 (m, 3H), 6.78-6.88 (m, IH), 7.03-7.57 (m, 12H), 8.11-8.20 (m, IH).
Example 44 2-(4'-Cyclopropylcarbamoyl-biphenyl-4-yl)-pyrrolidine-l-carboxylic acid benzyl ester
(Compound 4044)
A solution of N-cyclopropyl-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- benzamide (Example 10, 64.5 mg, 0.22 mmol), 2-(4-bromo-phenyl)-pyrrolidine-l- carboxylic acid benzyl ester (82.7 mg, 0.23 mmol), and Pd[P(Ph)3]4 (13.1 mg, 4.9 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 39.0 mg. MS: 441.2 (M+H+); H1 NMR (DMSO-de): £(ppm) 0.540.75 (m, 4H), 1.69-1.92 (m, 3H), 2.23-2.43 (m, IH), 2.79-2.90 (m, IH), 4.82-5.11 (m, 3H), 6.80-6.89 (m, IH), 7.04-7.41 (m, 6H), 7.57-7.95 (m, 6H), 8.42- 8.50 (m, IH).
Example 45
(S)-2-[6-(3-Acetyl-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4045)
From 1 eq. of l-(3-bromo-phenyl)-ethanone following General Procedure A. Yield 21 mg. MS: 440.5 (M+H+); H'-NMR (DMSO-d6): £(ppm) 8.1 (m, IH), 7.9 (m, 2H), 7.7 (m, 3H), 7.65 (m, IH), 7.3 (m, 3H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.66 (s, 3H), 2.02 (m, 4H).
Example 46
(S)-2-(6-Thiophen-3-yl-lH-benzoimidazol-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4046)
From 1 eq. of 3-bromo-thiophene following General Procedure A. Yield 10 mg. MS: 404.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 8.2-8.4 (m, 4H), 7.9 (m, IH), 7.7 (m, IH), 8.0-7.6 (m, 6H), 7.3 (m, 3H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H). Example 47
(S)-2-[6-(9H-Carbazol-3-yl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4047)
From 1 eq. of 3-bromo-9H-carbazole following General Procedure A. Yield 18 mg. MS: 489.5 (M-NHCOCH3); H'-NMR (DMSO-d6): £(ppm) 8.5 (s, IH), 8.2 (m, IH), 8.0-7.7 (m, 6H), 7.6 (m, IH), 7.5 (m, IH), 7.3 (m, 3H), 7.1-6.8 (m, 4H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 48
(S)-2- [6-(4-Cy clopropylcarbamoyl-phenyl)- lH-imidazo [4,5-b] pyridin-2-yl] - pyrrolidine-1-carboxylic acid benzyl ester (Compound 4048) (S)- 2-(3-Amino-5-bromo-pyridin-2-ylcarbamoyl)-pyrrolidine-l-carboxylic acid benzyl ester.
Z-protected (S)-proline (500 mg) was dissolved in DMF (15 mL) and treated with HATU (1.1 eq. 800 mg) and DIPEA (2.1 eq, 0.78 mL) and stirred for 15 minutes. 5-Bromo- pyridine-2,3-diamine (1 eq, 376 mg) was added and the mixture stirred at ambient temperature overnight. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. MS: 419.5 (M+H+) (S)- 2-(6-Bromo-lH-imidazo[4,5-b]pyridin-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester.
(S)-2-(3-Amino-5-bromo-pyridin-2-ylcarbamoyl)-pyrrolidine-l-carboxylic acid benzyl ester was dissolved in HOAc (50 rnL) and heated to 110 deg. C for 12 hours. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. MS: 401.5 (M+H+).
(S)-2-[6-(4-Cyclopropylcarbamoyl-phenyl)-lH-imidazo[4,5-b]pyridin-2-yl]- pyrrolidine-1-carboxylic acid benzyl ester (Compound 4048). A solution of (S)-2-(6-Bromo-lH-imidazo[4,5-b]pyridin-2-yl)-pyrrolidine-l- carboxylic acid benzyl ester (80mg, 0.2 mmol), N-cyclopropyl-4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-benzamide (Example 10, 1 eq), Pd[P(Ph)3J4 (5 mol %, 11 mg), in methanol (2 mL), NaHCO3 (sat. aq., 300 μL) and DMF (400 μL) was degassed and heated to 70 0C overnight in a sealed vial. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the products. Yield 8.2 mg. MS: 482.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 8.7 (m, IH), 8.5 (m, IH), 8.3 (m, IH), 7.9- 7.8 (m, 5H), 7.3 (m, 2H), 6.9-6.8 (m, 2H), 5.2-4.8 (m, 3H), 3.8 (m, IH), 3.5 (m, IH), 2.8 (m, IH), 2.42 (m, IH), 2.02 (m, 2H), 0.7-0.6 (m, 4H)
Example 49
(S)-2-[6-(4-Cyano-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4049)
From 1 eq. of benzonitrile-4-boronic acid following General Procedure B. Yield 27 mg. MS: 423.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) ) 8.02-7.8 (m, 8H), 7.37 (m, 3H), 7.0-6.8 (m, 2H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 50
(S)-2-[6-(2,4-Dimethoxy-pyrimidin-5-yl)-lH-benzoimidazol-2-yl]-pyrrolidine-l- carboxylic acid benzyl ester (Compound 4050)
From 1 eq. of 2,4-dimethoxy-pyrimidine 5-boronic acid following General Procedure B. Yield 11 mg. MS: 460.5 (M+H+); H'-NMR (DMSO-d6): £(ppm) 8.5 (s, IH), 7.9-7.5 (m, 5H), 7.3 (m, 5H), 7.0-6.8 (m, 2H), 6.5 (m, IH), 5.2-4.8 (m, 3H), 3.76 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 3.53 (m, 3H), 2.02 (m, 4H).
Example 51
(S)-2-[6-(2-Methyl-benzothiazol-5-yl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (compound 4051)
From 1 eq. of 5-Bromo-2-methyl-benzothiazole following General Procedure A. Yield 38 mg. MS: 469.6 (M+H+); H'-NMR (DMSO-d6): £(ppm) 8.2-7.7 (m, 7H), 7.3 (m, 2H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.83 (s, 3H), 2.02 (m, 4H). Example 52
(S)-2-[6-(2-Hydroxy-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4052)
From 1 eq. of 2-(5,5-Dimethyl-[l,3,2]dioxaborinan-2-yl)-phenol following General Procedure B. Yield 39 mg. MS: 414.5 (M+H+); H'-NMR (DMSO-d6): £(ppm) 7.9-7.6 (m, 4H), 7.4-6.8 (m, 8H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 53
(S)-2-[6-(3-Amino-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4053) From 1 eq. of 3-aminophenylboronic acid following General Procedure B. Yield 31 mg. MS: 413.5 (M+H+); H1 -NMR (DMSO-d6): £(ppm) 7.8-7.7 (m, 3H), 7.4 (m, 4H), 7.2 (m, 2H), 7.0-6.8 (m, 3H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H).
Example 54
(S)-2-[6-(3-Hydroxy-phenyl)-lH-benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4054)
From 1 eq. of 3-bromo-phenol following General Procedure A. Yield 22 mg. MS: 414.5 (M+H+); H!-NMR (DMSO-d6): £(ppm) 7.8-7.7 (m, 5H), 7.3 (m, 3H), 7.0-6.8 (m, 4H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.02 (m, 4H). Example 55
(S)-2-{[4-(4-Cyclopropylcarbamoyl-phenyl)-thiazol-2-ylamino]-methyl}-pyrrolidine-l- carboxylic acid benzyl ester (Compound 4055)
4-(2-Amino-thiazol-4-yl)-benzoic acid A solution of 4-acetyl-benzoic acid (10 g, 61 mmol), in HOAc (400 niL) at 55°C was treated with bromine (1 eq., 3.12 rnL) dropwise over 10 minutes. After 90 minutes the reaction was cooled, the acetic acid was removed, ethyl acetate (50 mL) was added and then removed to get rid of the remainder of the acetic acid.The crude bromo ketone was then dissolved in ethanol (200 mL) with NaOAc (12 g) and thiourea (leq. 4.4 g) added. The suspension was stirred at room temperature for 15 hours. The solvents were removed and the solids washed with water (3x 100 mL) then etheπethanol (4:1, 3x 100 mL) and dried to give the product as a tan solid. MS: 221.2 (M+H+).
4-(2-Amino-thiazol-4-yl)-N-cyclopropyl-benzamide
4-(2-Amino-thiazol-4-yl)-benzoic acid (4.4g, 20 mmol) was dissolved in DMF (100 mL) and treated with HATU (1.1 eq. 8.4 g) and DIPEA (2.1 eq, 7.5 mL) and stirred for 15 minutes. Then cyclopropyl amine (1.1 eq, 1.5 mL) was added and the mixture stirred at ambient temperature for 1 hour. The reaction was diluted with 100 mL of water, extracted with EtOAc (3x 100 mL) dried with brine (100 mL) and then Na2SO4 and the solvents removed. The resulting solid was triturated with ether to give the product >95% purity by HPLC. MS: 260.3 (M+H).
(S)-2-{[4-(4-Cyclopropylcarbamoyl-phenyl)-thiazol-2-ylamino]-methyl}-pyrrolidine-l- carboxylic acid benzyl ester (Compound 4055)
A solution of 4-(2-Amino-thiazol-4-yl)-N-cyclopropyl-benzamide (259 mg, 1 mmol), (S)-2-Formyl-pyrrolidine-l-carboxylic acid benzyl ester (1 eq., 233 mg) in methanol (1 mL) was treated with NaBH3CN (2 eq. 211 mg) and heated to 50 0C overnight in a sealed vial. Another portion OfNaBH3CN (100 mg) was added and the mixture heated for another 1 hour. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. Yield 20 mg. MS: 476.3 (M+H). H'-NMR (DMSO-d6): δ (ppm) 8.3 (s, IH), 7.8 (m, 5H), 7.3-7.1 (m, 8H), 5.1 (m, 4H), 3.5 (m, 2H), 3.3 (m, 2H), 1.9 (m, 4H), 0.7-0.5 (m, 4H). Example 56
(S)-2-[5-(4-Cyclopropylcarbamoyl-thiazol-2-yl)-lH-benzoimidazol-2-yl]-pyrrolidine-l- carboxylic acid benzyl ester (Compound 4056)
From 1 eq of 2-bromo-thiazole-4-carboxylic acid cyclopropylamide following General Procedure A. Yield 11.6 mg. MS: 488.5 (M+H+); H'-NMR (DMSO-d6): £(ppm) 8.5 (m, IH), 8.2 (m, 2H), 8.1 (m, IH), 7.8 (m, IH), 7.3 (m, 3H), 7.0-6.8 (m, 2H), 5.2-4.8 (m, 3H), 3.70 (m, IH), 3.55 (m, IH), 2.90 (m, IH), 2.02 (m, 4H), 0.71 (m, 4H).
Example 57
(S)-2-(6- {3- [(Cyclopr opanecarbonyl-amino)-methyl] -phenyl}- lH-benzoimidazol-2-yl)- pyrrolidine-1-carboxylic acid benzyl ester (Compound 4057)
A solution of (S)-2-[5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- benzoimidazol-2-yl] -pyrrolidine-1-carboxylic acid benzyl ester (90.6 mg, 0.20 mmol), cyclopropanecarboxylic acid 3-bromo-benzylamide (Example 23, 51.8 mg, 0.20 mmol), and Pd[P(Ph)3J4 (13.5 mg, 5.8 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 16.4 mg. MS: 495.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.56-0.72 (m, 4H), 1.51-1.66 (m, IH), 1.89-2.20 (m, 3H), 4.20-4.39 (m, 2H), 4.79-5.16 (m, 2H), 5.18-5.32 (m, IH), 6.76- 7.98 (m, 12H), 8.51-8.66 (m, IH).
Example 58
(S)-2-{6-[4-(Cyclopropanecarbonyl-amino)-phenyl]-lH-benzoimidazol-2-yl}- pyrrolidine-1-carboxylic acid benzyl ester (Compound 4058)
Cyclopropanecarboxylic acid (4-bromo-phenyl)-amide
4-Bromo-phenylamine (690 mg, 4.0 mmol) was dissolved in dichloromethane (30 mL), and the solution was cooled to 00C. DIPEA (1.38 mL, 7.9 mmol) was then added, and the reaction was stirred at 00C for 5 minutes. Then cyclopropanecarbonyl chloride (0.315 mL, 4.0 mmol) was added, and the reaction was stirred at 00C for 20 minutes. The reaction was quenched with distilled water, and the solvents were removed. The resulting mixture was redissolved in DMF (10 mL) and purified by reverse phase HPLC to give the desired product. (S)-2-{6-[4-(Cyclopropanecarbonyl-amino)-phenyl]-lH-benzoimidazol-2-yl}- pyrrolidine-1-carboxylic acid benzyl ester (Compound 4058)
A solution of (S)-2-[5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH- benzoimidazol-2-yl]-pyrrolidine-l-carboxylic acid benzyl ester (90 mg, 0.20 mmol), cyclopropanecarboxylic acid (4-bromo-phenyl)-amide (49.0 mg, 0.20 mmol), and
Pd[P(Ph)3J4 (13.0 mg, 5.6 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 15.0 mg. MS: 481.2 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.75-0.87 (m, 4H), 1.74-1.85 (m, IH), 1.92-2.21 (m, 3H), 3.65-3.78 (m, 2H), 4.80-5.16 (m, 2H), 5.19-5.32 (m, IH), 6.80- 7.15 (m, 2H), 7.23-7.45 (m, 2H), 7.56-7.93 (m, 8H), 10.26-10.37 (s, IH).
Example 59
(S)-2-(6-Bromo-lH-imidazo[4,5-b]pyridin-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4059) (S)-2-(3-Amino-5-bromo-pyridin-2-ylcarbamoyl)-pyrrolidine-l-carboxylic acid benzyl ester.
Z-protected (S)-proline (500 mg) was dissolved in DMF (15 mL) and treated with HATU (1.1 eq. 800 mg) and DIPEA (2.1 eq, 0.78 mL) and stirred for 15 minutes. Then 5- bromo-pyridine-2,3-diamine (1 eq, 376 mg) was added and the mixture stirred at ambient temperature overnight. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. MS: 419.3 (M+H+)
(S)-2-(6-Bromo-lH-imidazo[4,5-b]pyridin-2-yl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4059) (S)-2-(3-Amino-5-bromo-pyridin-2-ylcarbamoyl)-pyrrolidine-l -carboxylic acid benzyl ester was dissolved in HOAc (10 mL) and heated to 110 0C for 12 hours. The reaction was cooled, filtered and the solvents removed. The resulting mixture was redissolved in 5 mL of 90% DMF, 10% water with 0.1% TFA and purified by reverse phase HPLC to give the product. Yield 6.2 mg. MS: 401.5 (M+H+). H!-NMR (DMSO-d6): δ (ppm) 8.4 (m, IH), 8.1 (m, IH), 7.3 (m, 2H), 7.1-6.7 (m, 3H), 5.2-4.8 (m, 3H), 3.5 (m, 2H), 1.91 (m, 4H). Example 60
(S)-2-(4'-Cyclopropylcarbamoyl-biphenyl-3-ylethynyl)-pyrrolidine-l-carboxylic acid benzyl ester (Compound 4060)
A solution of (S)-2-(3-boronic acid-phenylethyny^-pyrrolidine-l-carboxylic acid benzyl ester (62.5 mg, 0.18 mmol), 4-bromo-N-cyclopropyl-benzamide (Example 10, 43.3 mg, 0.18 mmol), and Pd[P(Ph)3J4 (11.2 mg, 5.4 mol %) in methanol (2 mL), NaHCO3 (sat. aq., 300 μL), and DMF (400 μL) was degassed and heated to 700C overnight in a sealed vial. The reaction was cooled, filtered, and purified by reverse phase HPLC to give the desired product. Yield 10.1 mg. MS: 465.5 (M+H+); H1 NMR (DMSO-d6): £(ppm) 0.54- 0.70 (m, 4H), 1.86-2.28 (m, 3H), 2.78-2.90 (m, IH), 4.71-4.82 (m, 2H), 4.96-5.12 (m, 2H), 5.18-5.29 (m, IH), 7.30-7.90 (m, 13H), 8.41-8.8.49 (m, IH).
Biological Examples Example 1. Anti-Hepatitis C Activity
Compounds can exhibit anti-hepatitis C activity by inhibiting viral and host cell targets required in the replication cycle. A number of assays have been published to assess these activities. A general method that assesses the gross increase of HCV virus in culture is disclosed in U.S. Patent No. 5,738,985 to Miles et al In vitro assays have been reported in Ferrari et al J. ofVir., 73:1649-1654, 1999; Ishii et al, Hepatology, 29:1227-1235, 1999; Lohmann et al, J. of Bio. Chem., 274:10807-10815, 1999; and Yamashita et al, J. of Bio. Chem., 273:15479-15486, 1998.
Replicon Assay
A cell line, ET (Huh-lucubineo-ET) was used for screening of compounds of the present invention for inhibiting HCV replication. The ET cell line was stably transfected with RNA transcripts harboring a I3gc>luc-ubi-neo/NS3-37ET; replicon with firefly luciferase-ubiquitin-neomycin phosphotransferase fusion protein and EMCV-IRES driven NS3-5B polyprotein containing the cell culture adaptive mutations (E1202G; T1280I; Kl 846T) (Krieger at al, 2001 and unpublished). The ET cells were grown in DMEM (Dulbeco's Modified Eagle's Medium), supplemented with 10% fetal calf serum, 2 mM Glutamine, Penicillin (100 IU/mL)/Streptomycin (100 μg/mL), Ix nonessential amino acids, and 250 μg/mL G418 ("Geneticin"). They were all available through Life Technologies (Bethesda, MD). The cells were plated at 0.5-1.0 xlO4 cells/well in the 96 well plates and incubated for 24 hrs before adding testing compounds. Then the compounds were added to the cells to achieve a final concentration of 0. InM to 50 μM and a final DMSO concentration of 0.5%. Luciferase activity were measured 48-72 hours later by adding a lysis buffer and the substrate (Catalog number Glo-lysis buffer E2661 and Bright-Glo luciferase system E2620 Promega, Madison, WI). Cells should not be too confluent during the assay. Percent inhibition of replication was plotted relative to no compound control. Under the same condition, cytotoxicity of the compounds was determined using cell proliferation reagent, WST-I (Roche, Germany). The compounds showing antiviral activities, but no significant cytotoxicities were chosen to determine EC50 and TC50. For these determinations, a 10 point 2-fold serial dilution for each compound was used, which spans a concentration range of 1000 fold. EC50 and similarly TC50 values were calculated by fitting %inhibition at each concentration to the following equation:
% inhibition = 100%/[(IC50/[I])b +1] where b is Hill's coefficient. Preferably, when tested at lOOμM the compounds of this invention will exhibit a % inhibition of at least 30% and more preferably a % inhibition of at least 50%.
When tested at 10 μM, the compounds in Table 1 were found to have the indicated percent inhibition values shown in Table 2. Compounds of Table 1 with % inhibition of less than 1% are not included in Table 2, but may have greater activity when tested at higher concentrations. In some preferred embodiments compounds of Formula I will have a % inhibition of at least 20% when tested at 10 μM. In other embodiments the compounds of Formula I will have a % inhibition of at least 50% when tested at 10 μM.
Table 2
Figure imgf000077_0001
Figure imgf000078_0001
Formulation Examples
The following are representative pharmaceutical formulations containing a compound of the present invention.
Example 1: Tablet formulation
The following ingredients are mixed intimately and pressed into single scored tablets.
Figure imgf000078_0002
Example 2: Capsule formulation
The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
Figure imgf000079_0001
Example 3: Suspension formulation
The following ingredients are mixed to form a suspension for oral administration.
Figure imgf000079_0002
Example 4: Injectable formulation
The following ingredients are mixed to form an injectable formulation.
Figure imgf000079_0003
Example 5: Suppository formulation
A suppository of total weight 2.5 g is prepared by mixing the compound of the invention with Witepsol® H- 15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:
Figure imgf000079_0004

Claims

What is claimed is:
1. A compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof, wherein:
Figure imgf000080_0001
A is a 3-13 membered ring optionally substituted with -(R )m wherein said ring is selected from the group consisting of cycloalkyl, heterocyclic, aryl, and heteroaryl; each R2 is independently selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aryl, substituted aryl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, halo, hydroxy, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, nitro, thiol, alkylthio, and substituted alkylthio; m is 0, 1, 2, or 3;
L1 is a bond, C1-C3 alkylene, C1-C2 heteroalkylene, C2-C3 alkenylene, or C2-C3 alkynylene;
T is C2-C6 alkylene or C1-Cs heteroalkylene and forms a 4-8 membered ring with V and W; V and W are both CH, or one of V or W is CH and the other of V or W is N; p is 0, 1 or 2;
Y1 is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, halo, hydroxy, alkoxy, substituted alkoxy, =CH2, oxo, or two Y1 groups together with the atoms to which they are bound form a phenyl, 4-7 membered cycloalkyl, or 4-7 membered heterocyclic ring where the phenyl, cycloalkyl, or heterocyclic ring is itself optionally substituted with 1 to 2 Y2 groups; Y2 is independently selected from the group consisting of alkyl, substituted alkyl, halo, oxo, hydroxy, carboxyl, carboxyl ester, cyano, and alkoxy with the proviso that Y is not oxo when the ring to which it is attached is phenyl;
Z is selected from the group consisting of C(O), C(S), and -SO2-; R is selected from the group consisting of R1 , OR1 , OCH2R1 , and NRlaR! ;
R1 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and
Rla is selected from the group consisting of hydrogen, alkyl, and substituted alkyl.
2. A compound of claim 1 wherein A is selected from the group consisting of
Figure imgf000081_0001
Figure imgf000082_0001
3. A compound of any one of claims 1 to 2 wherein L1 is a bond.
4. A compound of any one of claims 1 to 2 wherein L1 is C2 alkynylene.
5. A compound of claim 1 wherein at least one of R2 is R3 -L- wherein R3 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; and L, defined in the R3-L- orientation, is selected from the group consisting of a bond, -O-, -S-, -CH2-, -CH2CH2-, -SCH2-, -C(O)-, -C(S)-, -NHC(O)-, -C(O)NH-, -SO2-, -SO2NH-, -SO2CH2-, -OCH2-, -CH2CH2NHC(O)-, -CH2CH2NHC(O)CH2-, -NHN=C(CH3CH2OCO)-, -NHSO2-, =CH-, -NHC(O)CH2S-,
-NHC(O)CH2C(O)-, spirocycloalkyl, -C(O)CH2S-, and -C(O)CH2O- provided that when L is =CH-, R3 is heterocyclic or substituted heterocyclic.
6. A compound of claim 5 wherein R is substituted phenyl.
7. A compound of claim 1 wherein V is C and W is N.
8. A compound of claim 1 wherein Z is C(O).
9. A compound of claim 1 wherein R is OCH2R1 and R1 is phenyl or substituted phenyl.
10. A compound of claim 1 wherein p is 1 and Y1 is selected from the group consisting of substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, and substituted heterocyclic.
11. A compound of claim 1 having Formula (II) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof, wherein:
Figure imgf000083_0001
one of E or F is -N= and the other of E or F is -S-, -O- or -NH-; each R is independently selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aryl, substituted aryl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, halo, hydroxy, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, nitro, thiol, alkylthio, and substituted alkylthio; m is 1 or 2; L1 is a bond, C1-C3 alkylene, C1-C2 heteroalkylene, C2-C3 alkenylene, or C2-C3 alkynylene;
T is C2-C6 alkylene or C1-Cs heteroalkylene and forms a 4-8 membered ring with V and W;
V and W are both CH, or one of V or W is CH and the other of V or W is N; p is 0, 1 or 2;
Y1 is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, halo, hydroxy, alkoxy, substituted alkoxy, =CH2, oxo, or two Y1 groups together with the atoms to which they are bound form a phenyl, 4-7 membered cycloalkyl, or 4-7 membered heterocyclic ring where the phenyl, cycloalkyl, or heterocyclic ring is itself optionally substituted with 1 to 2 Y2 groups; Y2 is independently selected from the group consisting of alkyl, substituted alkyl, halo, oxo, hydroxy, carboxyl, carboxyl ester, cyano, and alkoxy with the proviso that Y is not oxo when the ring to which it is attached is phenyl;
Z is selected from the group consisting of C(O), C(S), and -SO2-; R is selected from the group consisting of R1, OR1, OCH2R1, and NRlaR!; R1 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and Rla is selected from the group consisting of hydrogen, alkyl, and substituted alkyl.
12. A compound of claim 11 wherein L1 is a bond.
13. A compound of claim 11 wherein L1 is C2 alkynylene
14. A compound of claim 11 wherein at least one of R2 is R3 -L- wherein R3 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; and L, defined in the R3-L- orientation, is selected from the group consisting of a bond, -O-, -S-, -CH2-, -CH2CH2-, -SCH2-, -C(O)-, -C(S)-, -NHC(O)-, -C(O)NH-, -SO2-, -SO2NH-, -SO2CH2-, -OCH2-, -CH2CH2NHC(O)-, -CH2CH2NHC(O)CH2-, -NHN=C(CH3CH2OCO)-, -NHSO2-, =CH-, -NHC(O)CH2S-, -NHC(O)CH2C(O)-, spirocycloalkyl, -C(O)CH2S-, and -C(O)CH2O- provided that when L is =CH-, R3 is heterocyclic or substituted heterocyclic.
15. A compound of claim 14 wherein R3 is substituted phenyl.
16. A compound of claim 11 wherein V is C and W is N.
17. A compound of claim 11 wherein Z is C(O).
18. A compound of claim 11 wherein R is OCH2R1 and R1 is phenyl or substituted phenyl.
19. A compound of claim 11 wherein p is 1 and Y1 is selected from the group consisting of substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, and substituted heterocyclic.
20. A compound of claim 1 having Formula (III) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof, wherein:
Figure imgf000084_0001
one of E or F is -N= and the other of E or F is -S-, -O- or -NH-; each R is independently selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, acylamino, acyloxy, amino, substituted amino, aminocarbonyl, aryl, substituted aryl, carboxyl, carboxyl ester, cycloalkyl, substituted cycloalkyl, halo, hydroxy, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, nitro, thiol, alkylthio, and substituted alkylthio; m is 1 or 2;
L1 is a bond, C1-C3 alkylene, C1-C2 heteroalkylene, C2-C3 alkenylene, or C2-C3 alkynylene;
Q is selected from the group consisting of CH2, CH(Y1), C(Y1XY1), S, and O; p is 0, 1 or 2;
Y1 is independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, halo, hydroxy, alkoxy, substituted alkoxy, =CH2, oxo, or two Y1 groups together with the atoms to which they are bound form a phenyl, 4-7 membered cycloalkyl, or 4-7 membered heterocyclic ring where the phenyl, cycloalkyl, or heterocyclic ring is itself optionally substituted with 1 to 2 Y2 groups; Y2 is independently selected from the group consisting of alkyl, substituted alkyl, halo, oxo, hydroxy, carboxyl, carboxyl ester, cyano, and alkoxy with the proviso that Y is not oxo when the ring to which it is attached is phenyl;
Z is selected from the group consisting of C(O), C(S), and -SO2-;
R is selected from the group consisting of R1, OR1, OCH2R1, and NRlaR!; R1 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and
Rla is selected from the group consisting of hydrogen, alkyl, and substituted alkyl.
21. A compound of claim 20 wherein at least one of R2 is R3 -L- wherein R3 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; and L, defined in the R3-L- orientation, is selected from the group consisting of a bond, -O-, -S-, -CH2-, -CH2CH2-, -SCH2-, -C(O)-, -C(S)-, -NHC(O)-, -C(O)NH-, -SO2-, -SO2NH-, -SO2CH2-, -OCH2-, -CH2CH2NHC(O)-, -CH2CH2NHC(O)CH2-, -NHN=C(CH3CH2OCO)-, -NHSO2-, =CH-, -NHC(O)CH2S-, -NHC(O)CH2C(O)-, spirocycloalkyl, -C(O)CH2S-, and -C(O)CH2O- provided that when L is =CH-, R3 is heterocyclic or substituted heterocyclic.
22. A compound of claim 21 wherein R3 is substituted phenyl.
23. A compound of claim 20 wherein Z is C(O).
24. A compound of claim 20 wherein R is OCH2R1 and R1 is phenyl or substituted phenyl.
25. A compound of claim 20 wherein Q is S, CH2, or O.
26. A compound of claim 20 wherein p is 1 and Y1 is selected from the group consisting of substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic, and substituted heterocyclic.
27. A compound of claim 1 or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof selected from Table 1.
28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound, stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof of any one of claims 1 to 27.
29. A method for treating a viral infection in a patient mediated at least in part by a virus in the Flaviviridae family of viruses which method comprises administering to the patient a compound, stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof of any one of claims 1 to 27.
30. The method of claim 29 wherein said viral infection is a hepatitis C mediated viral infection.
31. The method of claim 29 in combination with the administration of a therapeutically effective amount of one or more agents active against hepatitis C virus.
32. The method of claim 31 wherein said agent active against hepatitis C virus is an inhibitor of HCV proteases, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, or inosine 5 '-monophosphate dehydrogenase.
33. The method of claim 31 wherein said agent active against hepatitis C virus is interferon.
PCT/US2007/085218 2006-11-21 2007-11-20 Anti-viral compounds WO2008070447A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07871535A EP2097405A2 (en) 2006-11-21 2007-11-20 Anti-viral compounds
US12/515,610 US20100055071A1 (en) 2006-11-21 2007-11-20 Anti-Viral Compounds
JP2009537412A JP2010510245A (en) 2006-11-21 2007-11-20 Antiviral compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86061406P 2006-11-21 2006-11-21
US60/860,614 2006-11-21

Publications (2)

Publication Number Publication Date
WO2008070447A2 true WO2008070447A2 (en) 2008-06-12
WO2008070447A3 WO2008070447A3 (en) 2009-03-05

Family

ID=39365701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/085218 WO2008070447A2 (en) 2006-11-21 2007-11-20 Anti-viral compounds

Country Status (5)

Country Link
US (2) US20080193411A1 (en)
EP (1) EP2097405A2 (en)
JP (1) JP2010510245A (en)
TW (1) TW200831084A (en)
WO (1) WO2008070447A2 (en)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
WO2010099527A1 (en) 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2010120935A1 (en) * 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
US7842685B2 (en) 2008-06-20 2010-11-30 Amgen Inc. S1P1 receptor agonists and use thereof
WO2010138790A1 (en) * 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
WO2011026920A1 (en) 2009-09-03 2011-03-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives
WO2011054834A1 (en) 2009-11-04 2011-05-12 Tibotec Pharmaceuticals Benzimidazole-imidazole derivatives
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
WO2011119870A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8097622B2 (en) 2008-10-14 2012-01-17 Daiichi Sankyo Company, Limited Morpholinopurine derivatives
WO2012013643A1 (en) 2010-07-26 2012-02-02 Tibotec Pharmaceuticals Hetero-bicyclic derivatives as hcv inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143301B2 (en) 2009-04-09 2012-03-27 Bristol Myers Squibb Company Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012528195A (en) * 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Antibacterial compounds composed of three linked aryl moieties for treating diseases such as hepatitis C
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013098313A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Hetero-bicyclic derivatives as hcv inhibitors
WO2013098320A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Quinazolinone derivatives as hcv inhibitors
US8486938B2 (en) 2010-06-24 2013-07-16 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines for antiviral treatment
WO2013118102A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a heterotricycle moiety
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8618153B2 (en) 2009-11-12 2013-12-31 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8809548B2 (en) 2009-02-17 2014-08-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8835449B2 (en) 2011-11-11 2014-09-16 Pfizer Inc. 2-thiopyrimidinones
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8946238B2 (en) 2011-12-22 2015-02-03 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
US8980878B2 (en) 2012-04-17 2015-03-17 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US9006455B2 (en) 2009-11-11 2015-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
WO2016180802A1 (en) 2015-05-13 2016-11-17 Bayer Cropscience Aktiengesellschaft Insecticidal arylpyrrolidines, method for synthesizing same, and use thereof as agents for controlling animal pests
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones
US9776981B2 (en) 2009-11-11 2017-10-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2020117849A1 (en) 2018-12-04 2020-06-11 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809344B2 (en) 2008-10-29 2014-08-19 Apath, Llc Compounds, compositions, and methods for control of hepatitis C viral infections
EP2430015B1 (en) 2009-05-12 2015-06-17 Merck Sharp & Dohme Corp. Fused tricyclic compounds useful for the treatment of viral diseases
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
MA34147B1 (en) * 2010-03-09 2013-04-03 Merck Sharp & Dohme SILYL FUSIONED TRICYCLIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF VIRAL DISEASES
CN103864753B (en) * 2014-02-27 2016-01-20 华东师范大学 Anti-third livering compound containing five yuan of fragrant heterocycle structures and preparation method and purposes
WO2016029146A1 (en) * 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
JP6616244B2 (en) * 2015-05-29 2019-12-04 北興化学工業株式会社 Novel hydroxyphenylboronic acid ester and method for producing the same, and method for producing hydroxybiphenyl compound

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801604A (en) * 1985-10-25 1989-01-31 The Upjohn Company Cis-N-(2-aminocycloaliphatic)benzamide anti-convulsants
WO1997041119A1 (en) * 1997-05-02 1997-11-06 Dr. Reddy's Research Foundation Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5707987A (en) * 1994-02-25 1998-01-13 Banyu Pharmaceutical Co., Ltd. Carbapenem derivatives
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
JP2001247569A (en) * 1999-08-12 2001-09-11 Japan Tobacco Inc Pyrrolidine derivative or piperidine derivative and its medicinal use
WO2002000631A2 (en) * 2000-06-29 2002-01-03 Fujisawa Pharmaceutical Co., Ltd. Benzhydryl derivatives
WO2003057667A2 (en) * 2001-12-31 2003-07-17 The Ohio State University Research Foundation Strapped and modified bis (benzimidazole) diamides for asymmetric catalysts and other applications
US6660759B1 (en) * 1999-08-30 2003-12-09 Fujisawa Pharmaceutical Co. Ltd. 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
US20060074071A1 (en) * 2004-09-29 2006-04-06 Chemocentryx, Inc. Substituted arylamides
US20060116515A1 (en) * 2004-12-01 2006-06-01 Kalypsys, Inc. Inducible nitric oxide synthase dimerization inhibitors
WO2006117669A1 (en) * 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds
WO2007070600A2 (en) * 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
WO2007077186A1 (en) * 2005-12-30 2007-07-12 Novartis Ag Pdf inhibitors
WO2007106192A2 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
WO2008021936A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673772B2 (en) * 1999-01-14 2004-01-06 Sumitomo Pharmaceuticals Company Limited Dipeptide compounds and their use as antiviral agents
JP2001247550A (en) * 1999-12-27 2001-09-11 Japan Tobacco Inc Condensed ring compound and its medicinal use
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2004014313A2 (en) * 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
UA92746C2 (en) * 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
US8143288B2 (en) * 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1976829A2 (en) * 2005-12-12 2008-10-08 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200827368A (en) * 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801604A (en) * 1985-10-25 1989-01-31 The Upjohn Company Cis-N-(2-aminocycloaliphatic)benzamide anti-convulsants
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US5707987A (en) * 1994-02-25 1998-01-13 Banyu Pharmaceutical Co., Ltd. Carbapenem derivatives
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
WO1997041119A1 (en) * 1997-05-02 1997-11-06 Dr. Reddy's Research Foundation Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
JP2001247569A (en) * 1999-08-12 2001-09-11 Japan Tobacco Inc Pyrrolidine derivative or piperidine derivative and its medicinal use
US6660759B1 (en) * 1999-08-30 2003-12-09 Fujisawa Pharmaceutical Co. Ltd. 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity
WO2002000631A2 (en) * 2000-06-29 2002-01-03 Fujisawa Pharmaceutical Co., Ltd. Benzhydryl derivatives
WO2003057667A2 (en) * 2001-12-31 2003-07-17 The Ohio State University Research Foundation Strapped and modified bis (benzimidazole) diamides for asymmetric catalysts and other applications
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
US20060074071A1 (en) * 2004-09-29 2006-04-06 Chemocentryx, Inc. Substituted arylamides
US20060116515A1 (en) * 2004-12-01 2006-06-01 Kalypsys, Inc. Inducible nitric oxide synthase dimerization inhibitors
WO2006117669A1 (en) * 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds
WO2007070600A2 (en) * 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
WO2007106192A2 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
WO2007077186A1 (en) * 2005-12-30 2007-07-12 Novartis Ag Pdf inhibitors
WO2008021936A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRIAN K. ALBRECHT AND ROBERT M. WILLIAMS: "A concise formal total synthesis of TMC-95A/B proteasome inhibitors" ORGANIC LETTERS, vol. 5, no. 2, 2003, pages 197-200, XP002508117 *
GHOTAS EVINDAR AND ROBERT A. BATEY: "Parallel synthesis of a library of benzoxazoles and benzothiazoles using ligand-accelerated copper-catalyzed cyclizations of ortho-halobenzanilides" JOURNAL OF ORGANIC CHEMISTRY, vol. 71, no. 5, 2006, pages 1802-1808, XP002508116 *
KAZUYUKI MAEKAWA AND JIRO OHTANI: "Synthese von 2-(1'-Amino-1'-substituiertem alkyl)-benzimidazol aus Aminosäuren und ihre biologische Aktivität" AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 40, no. 4, 1976, pages 791-799, XP008069983 ISSN: 0002-1369 *
ROGER JOYEAU ET AL: "Synthesis and activity of pyrrolidinyl- and thiazolidinyl-dipeptide derivatives as inhibitors of the Tc80 prolyl oligopeptidase from Trypanosoma cruzi" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 2, 2000, pages 257-266, XP004330419 ISSN: 0223-5234 *
ZHI-JIE NI AND ALLAN S. WAGMAN: "Progress and development of small molecule HCV antivirals" CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, vol. 7, no. 4, 2004, pages 446-459, XP009037092 ISSN: 1367-6733 cited in the application *

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842685B2 (en) 2008-06-20 2010-11-30 Amgen Inc. S1P1 receptor agonists and use thereof
US8097622B2 (en) 2008-10-14 2012-01-17 Daiichi Sankyo Company, Limited Morpholinopurine derivatives
US8309546B2 (en) 2008-10-14 2012-11-13 Daiichi Sankyo Company, Limited Morpholinopurine derivatives
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US9249138B2 (en) 2008-12-23 2016-02-02 Abbvie Inc. Anti-viral compounds
US9163017B2 (en) 2008-12-23 2015-10-20 Abbvie Inc. Anti-viral compounds
US8809548B2 (en) 2009-02-17 2014-08-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010099527A1 (en) 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8143301B2 (en) 2009-04-09 2012-03-27 Bristol Myers Squibb Company Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102459165B (en) * 2009-04-15 2015-09-02 Abbvie公司 Antiviral compound
WO2010120935A1 (en) * 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
CN102459165A (en) * 2009-04-15 2012-05-16 雅培制药有限公司 Anti-viral compounds
RU2541571C2 (en) * 2009-04-15 2015-02-20 Эббви Инк. Antiviral compounds
TWI471324B (en) * 2009-04-15 2015-02-01 Abbvie Inc Anti-viral compounds
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
JP2012528195A (en) * 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Antibacterial compounds composed of three linked aryl moieties for treating diseases such as hepatitis C
JP2012528194A (en) * 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Antibacterial compounds composed of three aligned aryl moieties for treating diseases such as hepatitis C
WO2010138790A1 (en) * 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10028937B2 (en) 2009-06-11 2018-07-24 Abbvie Inc. Anti-viral compounds
US9586978B2 (en) 2009-06-11 2017-03-07 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8921514B2 (en) 2009-06-11 2014-12-30 Abbvie Inc. Anti-viral compounds
US10039754B2 (en) 2009-06-11 2018-08-07 Abbvie Inc. Anti-viral compounds
US8691938B2 (en) 2009-06-11 2014-04-08 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
US8623899B2 (en) 2009-08-07 2014-01-07 Janssen Research & Development Ireland Bis-benzimidazole derivatives as hepatitis C virus inhibitors
WO2011026920A1 (en) 2009-09-03 2011-03-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives
US9433609B2 (en) 2009-11-04 2016-09-06 Janssen Sciences Ireland Uc Benzimidazole-imidazole derivatives
WO2011054834A1 (en) 2009-11-04 2011-05-12 Tibotec Pharmaceuticals Benzimidazole-imidazole derivatives
US9427428B2 (en) 2009-11-04 2016-08-30 Janssen Sciences Ireland Uc Benzimidazole-imidazole derivatives
US9776981B2 (en) 2009-11-11 2017-10-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9006455B2 (en) 2009-11-11 2015-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8618153B2 (en) 2009-11-12 2013-12-31 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8735398B2 (en) 2009-12-30 2014-05-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103038237A (en) * 2010-03-24 2013-04-10 沃泰克斯药物股份有限公司 Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119870A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8686026B2 (en) 2010-06-10 2014-04-01 Abbvie Inc. Solid compositions
US8809330B2 (en) 2010-06-24 2014-08-19 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
US8486938B2 (en) 2010-06-24 2013-07-16 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines for antiviral treatment
US9957275B2 (en) 2010-06-24 2018-05-01 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
US9238039B2 (en) 2010-06-24 2016-01-19 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines for antiviral treatment
WO2012013643A1 (en) 2010-07-26 2012-02-02 Tibotec Pharmaceuticals Hetero-bicyclic derivatives as hcv inhibitors
US8815849B2 (en) 2010-07-26 2014-08-26 Janssen R&D Ireland Hetero-bicyclic derivatives as HCV inhibitors
US9340520B2 (en) 2011-02-07 2016-05-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9399626B2 (en) 2011-11-11 2016-07-26 Pfizer Inc. 2-thiopyrimidinones
US8835449B2 (en) 2011-11-11 2014-09-16 Pfizer Inc. 2-thiopyrimidinones
US9873673B2 (en) 2011-11-11 2018-01-23 Pfizer Inc. 2-thiopyrimidinones
US8841314B2 (en) 2011-11-11 2014-09-23 Pfizer Inc. 2-Thiopyrimidinones
US9278975B2 (en) 2011-12-22 2016-03-08 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
US8946238B2 (en) 2011-12-22 2015-02-03 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
WO2013098320A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Quinazolinone derivatives as hcv inhibitors
US9382261B2 (en) 2011-12-28 2016-07-05 Janssen Sciences Ireland Uc Substituted quinazolinones as HCV inhibitors
WO2013098313A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Hetero-bicyclic derivatives as hcv inhibitors
US9126986B2 (en) 2011-12-28 2015-09-08 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as HCV inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9073942B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a heterotricycle moiety
WO2013118097A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
WO2013118102A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a heterotricycle moiety
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US10174038B2 (en) 2012-04-17 2019-01-08 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US9504689B2 (en) 2012-04-17 2016-11-29 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US8980878B2 (en) 2012-04-17 2015-03-17 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9770439B2 (en) 2013-07-02 2017-09-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US10105365B2 (en) 2014-01-03 2018-10-23 Abbvie Inc. Solid antiviral dosage forms
US9744170B2 (en) 2014-01-03 2017-08-29 Abbvie Inc. Solid antiviral dosage forms
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones
WO2016180802A1 (en) 2015-05-13 2016-11-17 Bayer Cropscience Aktiengesellschaft Insecticidal arylpyrrolidines, method for synthesizing same, and use thereof as agents for controlling animal pests
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2020117849A1 (en) 2018-12-04 2020-06-11 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring

Also Published As

Publication number Publication date
US20100055071A1 (en) 2010-03-04
WO2008070447A3 (en) 2009-03-05
EP2097405A2 (en) 2009-09-09
JP2010510245A (en) 2010-04-02
US20080193411A1 (en) 2008-08-14
TW200831084A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
WO2008070447A2 (en) Anti-viral compounds
US7629340B2 (en) N-(6-membered aromatic ring)-amido anti-viral compounds
US8729077B2 (en) Anti-viral compounds, compositions, and methods of use
US20090317360A1 (en) Anti-viral inhibitors and methods of use
EP2099778A2 (en) Amido anti-viral compounds
US7595398B2 (en) N-(5-membered aromatic ring)-amido anti-viral compounds
US20070032488A1 (en) 6-Membered aryl and heteroaryl derivatives for treating viruses
US20060293320A1 (en) Heteroaryl derivatives for treating viruses
EP1844042A1 (en) Indole derivatives for treating viral infections
WO2009143361A1 (en) Amido anti-viral compounds
WO2008008912A1 (en) Antiviral agents
WO2008011521A2 (en) Polycyclic viral inhibitors
US20100061960A1 (en) Amido Anti-Viral Compounds, Compositions, And Methods Of Use
US20080051384A1 (en) Antiviral agents
WO2009143359A2 (en) Amido anti-viral compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871535

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009537412

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007871535

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12515610

Country of ref document: US